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ABSTRACT OF THE DISSERTATION 
IDENTIFICATION AND PHENOTYPIC PLASTICITY OF METASTATIC CELLS 
IN A MOUSE MODEL OF MELANOMA 
by 
Xiaoshuang Li 
Florida International University, 2017 
Miami, Florida 
Professor Lidia Kos, Major Professor 
Melanoma is the deadliest form of skin cancer due to its high propensity 
to metastasize and resistance to current therapies. We have created a 
spontaneous mouse model of metastatic melanoma (Dct-Grm1/K5-Edn3) 
where metastasis to the lungs is 80% penetrant. The primary tumors of these 
mice present cellular heterogeneity with cells at varying levels of differentiation. 
The main goal of this study was to determine the metastatic potential of the 
primary tumor resident Tyrosinase positive cells and evaluate the dynamic 
phenotypic changes as those cells move from the primary tumors to the sites of 
metastasis. To accomplish this aim I crossed the Dct-Grm1/K5-Edn3 mice to 
CreERT2/mT/mG mice to indelibly label Tyrosinase cell populations within the 
primary tumor with Green Fluorescent Protein (GFP) by topical application of 4-
hydroxytamoxifen (4HT) at the tumor site. In vivo lineage tracing and 
characterization of GFP+ cells were performed in the metastatic lesions. 
In the 4HT treated Dct-Grm1/ K5-Edn3/Tyr-CreERT2/mT/mG mice, 
primary tumor derived Tyrosinase positive cells or their progeny (GFP+) 
 viii 
established successful metastases in the distant organs indicating the 
tumorigenic capacity of the differentiated cell populations. Numerous metastatic 
melanoma cells were identified in the vasculature of the metastatic organs and 
established close association with the vascular endothelium. The intravascular 
cells lost pigmentation and did not express melanocytic markers; however, they 
mimicked endothelial cell properties and gained the expression of CD31 (also 
known as platelet endothelial cell adhesion molecule PECAM-1) and vascular 
endothelial (VE)-Cadherin. In the lung metastatic foci, GFP+ cells resumed 
pigmentation production and lost the expression of endothelial cell markers. 
Evidence from other metastatic organs in the mice further supported the 
phenotypic plasticity of metastatic melanoma cells.  
The in vivo lineage tracing system established in the melanoma mouse 
model revealed tumor phenotypic plasticity and will be a powerful model to 
evaluate and help us understand the etiology and pathogenesis of melanoma 
metastasis. Further characterization of those more aggressive cells in 
melanoma will allow for the development of new prognostic tests and novel 
therapeutic strategies to eliminate metastasis. 
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CHAPTER 
 
1. INTRODUCTION 
  
 2 
1.1 Introduction 
Most cancer patients die of metastasis [1]. Cancer metastasis is the 
spread of a cancer from one organ or part of the body to another organ or part of 
the body that is not directly connected. The process of metastasis consists of a 
series of interconnected, sequential or parallel steps that must be completed by 
tumor cells if a metastasis is to develop, although the exact steps for individual 
tumors are widely context-dependent. The vasculature plays essential roles 
during cancer metastasis. In addition to the authentic endothelial cell-lined 
vasculature, new models of vasculature, such as vasculogenic mimicry, vessel 
co-option and cancer cell-derived endothelial cells, have been reported [2]. 
Mechanisms underlying tumor metastasis are still under investigation, among 
which epithelial-mesenchymal transition (EMT) is receiving increasing attention 
[3, 4]. 
Melanoma is the type of skin cancer that causes the most deaths because 
of its high metastatic potential. Progression of normal melanocytes to metastatic 
melanoma was thought to be linear, but recent evidence has suggested it is more 
complex and less linear in nature [5]. Clinical cases of late recurrence after the 
initial primary melanoma resection [6] not only implicated the early dissemination 
of tumor cells, but also suggested melanoma dormancy. Although a number of 
studies have proposed an important role for cancer stem cells (CSCs) in 
melanoma, their existence and relevance remain a controversial issue [7]. The 
role of circulating tumor cells (CTCs) in metastatic colonization is also extensively 
discussed [8, 9]. In this chapter, steps of cancer metastasis are summarized and 
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the putative roles of EMT in metastasis are reviewed. In addition, descriptions of 
melanoma progression and dormancy are introduced as well as the current 
available evidence for metastasis-initiating cells focusing on CTCs. 
1.2 Cancer Metastasis 
1.2.1 Steps in Metastasis 
Cancer metastasis involves several steps; metastatic cancer cells leave 
the primary tumor, travel to distant organs through various mechanisms and 
eventually seed metastases in the secondary organs. Blood/lymphatic 
vasculature plays essential roles in cancer metastasis by providing a route for the 
travel of cancer cells from primary sites to secondary sites. As malignant cancer 
cells start to proliferate out of control, a solid mass will appear as the primary 
tumor. Further growth of the primary tumor was originally believed to be 
angiogenesis-dependent and neovascularization was needed for tumor invasion 
and metastasis [10]. The promise of this hypothesis has been subjected to 
clinical evaluations and anti-angiogenesis agents have been used as standard-
of-care therapies for various types of cancers [11]. Later, this classic concept 
was challenged by studies showing that micro-tumors may initiate tumor growth 
by hijacking the pre-existing host vessels, a process known as vessel co-option 
(also known as vascular co-option), without inducing angiogenesis in a 
vascularized tissue [12-15]. Vessel co-option is also responsible for tumor 
progression after anti-angiogenesis therapies [16-19]. Other than the endothelial 
cell-lined vasculature in tumors, aggressive tumor cells can form blood-perfused 
tubular channels, termed as vasculogenic mimicry (VM), linking directly to normal 
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vessels for the blood supply of the tumor growth [20]. Although aggressive uveal 
melanoma cells engaged in the formation of VM in 3D Matrigel downregulated 
invasiveness related genes [21], VM is strongly associated with clinical deaths of 
metastasis in uveal and cutaneous melanoma patients [22, 23]. The plasticity of 
tumor cells to gain an endothelial-like phenotype is depicted in another form of 
vasculature in cancer, the mosaic vessels. Tumor cells can mimic endothelial 
cells by participating in the formation of blood vessels. Mosaic vessels are 
marked by discontinued endothelial cell marker CD31 expression and the 
replacement of some endothelial cells with tumor cells in the vessels [24]. It is 
reasonable to propose that the presence of cancer cells within the mosaic 
vessels in contact with the blood lumen indicate tumor dissemination and 
metastasis [25]. Recent observations in glioma adds another layer to the role 
played by the tumor vasculature in that glioma cells can transdifferentiate into 
endothelial cells and express endothelial cell markers [26-31]. 
Several interactions or phenomena between cancer cells and the 
vasculature have been suggested or observed. The well-studied interaction 
between cancer cells and blood vessels is transendothelial migration. Tumor 
cells can migrate through the vascular endothelium to reach the blood 
(intravasation) and after transport in the blood stream, some cells can get out of 
the vasculature (extravasation) to seed metastases. Tumor cells within the blood 
stream are called circulating tumor cells (CTCs). Metastatic tumor cells can enter 
circulation as single cells or as cell clusters [32]. Circulating tumor cells have 
been successfully isolated from human blood in several cancers [33-36]. During 
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hematogenous dissemination, intravascular rolling behavior of metastatic cancer 
cells has been reported [37-41]. In contrast to intravascular dissemination or 
migration, Lugassy and Barnhill suggested “angiotropism” in melanoma as a new 
mechanism of tumor spread. They termed this phenomenon as 'extravascular 
migratory metastasis' (EVMM), emphasizing the pericytic mimicry of tumor cells. 
Extravascular migratory metastasis describes the continuous migration of tumor 
cells along the abluminal vascular surfaces to nearby or more distant sites [42-
44]. The similarity of vessel co-option and angiotropism and the significance of 
these mechanisms during the metastatic process have been further discussed in 
a brain melanoma mouse model [15]. 
At the metastatic sites, tumor cells reach the metastatic organs by 
whichever migration mechanism (extravasation, vessel co-option, EMVV) and 
start to proliferate and seed successful metastases. Intravascular proliferation of 
tumor cells has been suggested as an alternative origin of early metastasis in the 
lung [40, 45]. Instead of angiogenesis switch for further growth of metastatic 
tumors, vessel co-option is common in vasculature-rich tissues [18]. The overall 
process of cancer metastasis is summarized in Figure. 1.1. 
1.2.2 Mechanisms underlying Metastasis 
1.2.2.1 Epithelial-mesenchymal transition 
Epithelial-mesenchymal transition was originally defined in developmental 
biology as a conversion from embryonic epithelia to individual mesenchymal cells 
that can invade and migrate through the extracellular matrix (ECM) [46]. During 
normal development, epithelial cells provide cell-cell adhesion essential to 
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establish a barrier to the external environment for the development of embryos. 
In contrast, mesenchymal cells are free to rearrange or move around in three 
dimensions thus adding more plasticity for body patterning and morphogenesis 
[47]. Epithelial-mesenchymal transition involves not only morphological changes 
but also gene expression switch, in particular, the downregulation of E-cadherin 
and upregulation of N-cadherin. It took a long time for EMT to be recognized as a 
potential mechanism underlying carcinoma progression. Since local invasion is 
the first step for cancer metastasis, it is essential for tumor cells to lose cell-cell 
adhesion and acquire invasive or migratory behaviors. The similarities between 
the tumor malignancy switch and the developmental signature have solidified the 
notion that EMT is a major contributor to the escape of tumor cells from the 
primary tumors [48]. 
Although clinically carcinomas (tumors of epithelial origin) and sarcomas 
(tumors of mesenchymal origin) are generally not thought to interconvert, various 
carcinoma cell lines undergo EMT during specific culturing conditions in vitro [49]. 
The first evidence of EMT in cancer was noted by studies demonstrating that 
invasiveness and adoption of a fibroblast morphology can be achieved by down 
regulation of E-cadherin expression in various epithelial cancer cell lines [50, 51]. 
In addition, re-expression of E-cadherin can reverse the invasive property of 
cancer cells [50, 52, 53]. Transforming growth factor-beta (TGF-) was shown to 
be a main inducer in the cancer EMT process. Transformed mammary epithelial 
cells exhibited fibroblastoid properties in the presence of TGF-, the converted 
cells themselves produced high levels of TGF-1 and maintained a highly 
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invasive phenotype both in vitro and in vivo. Neutralization of TGF- reverted the 
epithelial phenotype of the fibroblastoid cells [54]. Blockage of TGF- receptor 
abolished metastasis formation in highly metastatic mesenchymal mouse colon 
carcinoma cells [55]. However, because of the numerous biological interactions 
TGF- is involved in, the interpretation that EMT occurs in response to TGF- is 
complex [56]. The understanding of EMT in cancer advanced when specific 
transcriptional modulators of E-cadherin gene promoter were identified. In 2000, 
two groups showed strong evidence that Snail1 binds directly to the promoter of 
E-cadherin and represses the transcription of this gene in invasive mouse and 
human carcinoma cell lines [57, 58]. Other Zn (zinc)-finger transcription factors, 
including Snail2 [59], ZEB1 [60], ZEB2 [61], were also shown to directly bind to 
the E-boxes of the E-cadherin promoter to repress its transcription. In addition to 
these Zn-finger transcription factors, ectopic expression of bHLH family 
transcription factor Twist1 resulted in the loss of E-cadherin mediated cell-cell 
adhesion, expression of mesenchymal markers and induction of cell motility, 
hallmarks of EMT in normal mammalian cells. Suppression of Twist in highly 
metastatic mammary carcinoma cells inhibited their metastatic capacity from the 
mammary gland to the lung in a murine breast tumor model [62]. Correlations 
between Twist1 and Snail2 during EMT in cancer metastasis were also 
discussed [63]. Other signaling pathways underlying EMT include bone 
morphogenetic protein (BMP), Wnt–β-catenin, Notch signaling, Hedgehog 
signaling, and receptor tyrosine kinases. In addition, environmental factors such 
as hypoxia and ECM also contribute to EMT process [64, 65]. 
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Nonetheless, the abundant stromal fibroblasts and the dynamics of EMT 
challenge our interpretation of EMT in human tumors [4]. Although numerous 
clinical studies correlate EMT with poor clinical outcomes, direct evidence is 
better demonstrated from the studies of CTCs. By lineage tracing, epithelial-
origin CTCs acquiring EMT phenotype were identified in a mouse model of 
pancreatic cancer [66]. Another study, using a spontaneous squamous cell 
carcinoma mouse model, showed that activation of EMT by Twist1 induction 
increased CTCs over 2-fold compared with the control group, most important, 
these CTCs exhibited mesenchymal marker expression [67]. In a human breast 
cancer xenograft mouse model, Bonnomet et al. showed that EMT in the primary 
tumor was associated with an enhanced number of CTCs that expressed 
mesenchymal markers Snail, Slug and Vimentin [68]. Circulating tumor cells with 
an EMT feature have also been reported in human patients, including breast 
cancer, lung, colorectal, prostate, bladder, ovarian, and endometrial cancers [69-
71]. 
1.2.2.2 EMT and Stemness 
Cancer stem cells (CSCs), also known as cancer-initiating cells, are those 
cells that have the ability to perpetuate themselves through self-renewal and to 
generate mature cells of a particular tissue through differentiation [72]. Cancer 
stem cells share similar stemness as regular stem cells in developmental 
processes. Recent studies have correlated EMT with stemness or CSCs.  Mani 
and colleagues showed immortalized human mammary epithelial cells acquired 
the expression of stem-cell markers after EMT induction, and those transformed 
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cells exhibited stem-cell properties by a higher efficiency in mammosphere and 
tumor formation [73]. In the context of cancer metastasis, the relationship 
between EMT and tumor-initiating capacity is better identified by studies on 
CTCs. Circulating tumor cells isolated from breast cancer patients showed EMT 
and stem cell characteristics, and inclusion of EMT markers to optimize CTCs 
detection was suggested [74-76]. In another study, a cell subpopulation with both 
tumor-initiating feature (CD44+/CD24−/low) and in vitro mammosphere-forming 
potential was identified in conventional therapy treated breast cancer samples. 
The increased expression of mesenchymal markers in this cell subpopulation has 
related EMT with tumor-initiating cells [77]. In a study of epithelial lineage tracing 
in a mouse model of pancreatic cancer, the authors showed that epithelial-
derived CTCs expressed mesenchymal markers, and further characterized the 
tumor initiating properties of those cells by transplantation [66]. However, not all 
cells that have undergone EMT possess stem cell-like properties, as is shown by 
the study in a spontaneous model of EMT using a primary prostate cancer 
derived cell line [78]. The cross talk between EMT and stemness is far more 
complex than expected. Different research groups have demonstrated that EMT 
can suppress the tumor-initiating capacities of human epithelial cells [79]. 
Epithelial-mesenchymal transition and stemness may be coupled, antagonistic or 
independent processes in cancer metastasis [80]. 
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1.3 Melanoma Skin Cancer 
1.3.1 Melanoma Progression 
Cutaneous melanoma has been one of the fastest rising cancers over the 
past several decades. According to the American Cancer Society, about 87,110 
new melanomas will be diagnosed and 9,730 people are expected to die of 
melanoma in 2017. Melanoma is notorious for its tendency to metastasize and 
for its poor response to current therapeutic regimens. 
Melanoma results from the malignant proliferation of melanocytes, the 
pigment producing cells in the skin. The classic paradigm describing the 
progression of normal melanocytes to metastatic melanoma is linear [81, 82]. 
Melanoma starts from the melanocytic nevus, a benign precursor lesion, followed 
by the dysplastic nevus. The first malignant stage of melanoma is called the 
radial growth phase (RGP). At RGP, transformed melanocytes start to spread 
laterally, but remain close to the epidermis and still under the control of the 
growth factors from the keratinocytes. The continuing invasion of melanocytes 
from basement membrane to the upper epidermis and lower dermis leads to the 
next stage, vertical growth phase (VGP). At VGP, melanocytes completely 
escape from the keratinocyte signals and new interactions between surrounding 
stroma cells are established. Melanocytes at VGP have the potential to 
disseminate and seed distant metastases in other organs [81-83]. 
However, the progression of melanoma may not be sequential or linear; 
emerging evidence both in mouse models and clinical observations suggest a 
much more elaborate view of melanoma metastasis [5]. In contrast to the 
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traditional notion that metastasis is a late event in tumor progression and it only 
occurs after the completion of all the required stages, early dissemination of 
abnormal cells was detected in both murine models and human samples. 
Husemann performed a comprehensive study about the early dissemination of 
breast cancer cells in both HER-2 and PyMT transgenic mice. In these breast 
cancer mouse models, transformed epithelial cells disseminated early from the 
atypical hyperplastic areas and those early disseminating cells can grow into 
metastases. Another finding of this study is that the dissemination of tumor cells 
was not associated with tumor size both in the mouse model and ductal 
carcinomas in situ in women [84]. A similar study using PyMT mice identified the 
stem cell property of some early disseminating cells. The disseminating and 
tumorigenic potential of the disseminating cells was further assessed by 
transplantation assay using GFP PyMT mice [85].  In a study by Podsypanina et 
al., untransformed mouse mammary cells in circulation were able to acquire 
malignant growth upon oncogene activation. They demonstrated this by 
introducing the premalignant mammary cells into circulation directly without going 
through the transformation within the primary tumors. Although they could not 
show the timing of the dissemination, they argued the possibility that 
untransformed cells that disseminated early could account for the later 
metastases [86]. Early dissemination before tumor formation was also reported in 
a pancreatic tumor mouse model, in which cells disseminated at premalignant 
stage reached the liver as single cells albeit no micro- or macro-metastases were 
observed [66]. In the spontaneous melanoma mouse model RET.AAD, early 
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dissemination of melanoma cells before primary tumor formation was identified 
through a series of assays, including SNP genetic analysis, IHC, RT-PCR and 
H&E staining. The authors also noted the dormancy of disseminating tumor cells 
in the lung [87]. Clinically, numerous cases of patients with metastatic melanoma 
free of detectable primary tumors have been reported [88-93]. 
1.3.2 Melanoma Dormancy 
Malignant melanoma is one of the two malignancies with the highest 
donor tumor transmission rates (74% transmission rate with 58% mortality) in 
human transplantations [94]. Organs from donors with melanoma history but free 
of disease for more than 10 years after initial surgery can present with recurrent 
metastasis in organ recipients. Late recurrence of melanoma after the initial 
primary tumor resection is reported [6]. Although various adjuvant therapies are 
designed to prevent the development of local recurrences or metastasis by 
targeting “residual” disease, the results have not necessarily been successful. 
Why is it that the “residual” tumor cells are so persistent? The answer may lie in 
the fact that the biology of some “residual” cells, that may disseminate into other 
organs before the removal of primary tumors, seem to be highly divergent from 
that of the primary tumor and/or overt metastasis [95]. All clinical observations 
listed previously point to an increasing concern surrounding melanoma-
metastatic dormancy, which may be the underlying cause for the incomplete cure 
of melanoma. 
Although a handful of reviews on melanoma dormancy are available [96-
98], the number of studies specifically focusing on this phenomenon in 
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melanoma is very limited compared with that for breast and prostate cancers. 
Despite the well documented clinical observations, evidence of melanoma 
dormancy in mouse models, which could serve as a useful tool to reveal the 
mechanisms underlying human disease, is scarce. An early study by Cameron et 
al. showed dormancy of solitary melanoma cells in lung using B16F10 cell 
injection. They concluded that solitary cell dormancy is a post-extravasation 
event contributing to metastasis inefficiency [99]. A similar study, where human 
melanoma cells were injected into the tail vein of immunodeficient mice, 
demonstrated that single or clusters of <10 cells in the lung failed to proliferate in 
vivo up to 60 days but retained tumor initiating capacity after in vitro culture [100]. 
Another study employing in vivo imaging showed that uveal melanoma cells can 
persist in the liver for 6 weeks in a dormant state [101]. Nonetheless, these 
studies did not provide or propose the underlying mechanisms for how these 
cells kept dormant and were able to escape immune attack in the metastatic 
organs. Without a mechanistic understanding, the evidence of melanoma 
dormancy in humans or mice is of little use in reducing recurrence or increasing 
survival of patients. A very recent study by Touil et al. may offer more clues on 
melanoma dormancy. In their study, they obtained a mouse model of melanoma 
dormancy through melanoma-based immunotherapy and ascertained the in vivo 
existence of immune-resistant dormant melanoma cells in different organs by 
qRT-PCR one year after the immunotherapy challenge. Unfortunately, no spatial 
information of those dormant cells was reported and the following 
characterization of the dormant cells was done through in vitro study of the 
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dormant cell-derived cell lines. Although they provided evidence that the dormant 
cells presented stem-like properties and that the GILZ/FOXO3A pathway was 
involved in the quiescence of those cells, these in vitro results are not as 
convincing as in vivo characterization [102]. 
1.3.3 Melanoma and Metastasis-Initiating Cells 
Melanoma is less common, but more serious than other types of skin 
cancers because of its high metastatic potential. The cellular composition of 
tumors is heterogeneous; there are many subpopulations of cells within the same 
tumor. Some cells are more differentiated, some are less differentiated showing a 
stem cell-like phenotype. Recent evidence suggested that the less differentiated 
cell population (i.e.,CSCs) may be responsible for tumor initiation and resistance 
to therapies [72]. Although several melanoma stem cell markers have been 
described [103-107], the robustness of these markers is questionable 
considering the limitations of the xenotransplantation assay that is widely used in 
cancer stem cell studies. In addition, the tumor initiating capacity of CSCs in 
melanoma was mainly discussed in the context of primary tumor formation and 
little is known about metastasis-initiating capacities. The differentiation levels of 
melanocytes with respect to their ability to metastasize was discussed by 
Damsky et al. Microphthalmia-associated transcription factor (MITF) and WNT/ -
catenin signaling are the known players controlling melanocyte differentiation, but 
their effects on melanoma metastasis seem to be context-dependent. Two 
hypotheses have been proposed to explain the controversial effects of the two 
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players on metastasis: the proper balance in the degree of differentiation, and the 
phenotypic plasticity of melanoma cells [5]. 
If during metastasis, the dissemination of tumor-initiating cells is required, 
presence of circulating tumor-initiating cells should be associated with worse 
patient outcome. A study demonstrated that CD133 and Nestin were expressed 
on CTCs, and those CTCs showed a similar expression profile with the matched 
metastatic lesions [108]. Another corroborating study demonstrated that Nestin 
was expressed in a proportion of melanoma cells enriched from peripheral blood 
of melanoma patients, and the expression level of Nestin was higher in stage IV 
patients compared with stage III ⁄ IV patients [109]. Clonal dominance of CD133 
in primary tumors of patients with recurrence or metastatic lesions was found, 
suggesting that CD133 subpopulation may be a determinant of tumor 
metastasis/tumor relapse [105]. Another study using experimental metastasis 
models, showed that the WNT receptor, FZD7, was required for the initiation and 
proliferation of metastatic melanoma growth [110]. In addition, Frank’s group has 
identified a subpopulation of tumor-initiating cells in melanoma by ABCB5 
expression [111]. Later they showed that human melanoma CTCs contain 
tumorigenic cell subpopulations capable of causing metastases, most 
interestingly, ABCB5-positive tumor cells were highly enriched among melanoma 
CTCs compared to either primary tumors or pulmonary metastases [112]. 
1.4 Research Questions 
 
Although efforts to identify melanoma-initiating cells (MICs) or CSCs are 
increasing and strong evidence is emerging, connections between MICs and 
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metastasis still remain an open question. This is partly because of the complexity 
of tumor progression in that both external and internal factors may account for 
tumor metastasis. Another reason is the lack of good melanoma metastasis 
models. For obvious reasons, it is impossible to follow a specific cell population 
in human melanoma patients from the primary tumor to the metastatic sites to 
check their metastasis-initiating capacity. Proper mouse melanoma metastasis 
models are very limited and in vivo tracing of cells requires numerous optimized 
conditions, such as timing of metastasis formation and visualization of interested 
melanoma cells. The effort to fully characterize melanoma metastasis-initiating 
cells is worthwhile because it will not only enhance our understanding of 
melanoma metastasis, but also provide insights for the development of 
metastasis-targeted therapies. 
Phenotypic plasticity of cancer cells is a well-recognized phenomenon; we 
know that tumor cells can switch gene expression profiles as necessary to best 
adapt to the environment. However, to what extent and how these changes are 
related to the spatial or temporal dimensions of tumor progression have not been 
sufficiently investigated. Histological and morphological dynamics may be 
observable through real-time in vivo imaging on zebrafish models or mouse 
models for a short period, while genetic changes are hard to be characterized in 
those setups. A detailed lineage tracing study in melanoma has not been 
pursued. As such, the establishment of an in vivo lineage tracing system of the 
tumorigenic cell subpopulations in a spontaneous mouse model of melanoma 
metastasis is essential. This system will not only delineate the tumor-initiating 
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capacity of specific cell subpopulations in the context of metastasis but also 
indicate the phenotypic plasticity of the metastatic cells (Figure 1.2). My overall 
hypothesis is that the primary tumor derived cell subpopulation with a more 
differentiated state possesses metastasis-initiating capacities and exhibit 
phenotypic plasticity during the metastatic process. To test this hypothesis, I 
addressed the following questions: 
Question 1: Can primary tumor derived cell subpopulations with a more 
differentiated state reach the secondary organs and seed successful 
metastases? 
I created a spontaneous melanoma metastasis mouse Tg (Grm1) Epv / 
K5-tTA-Edn3 (referred to as Dct-Grm1/ K5-Edn3) where metastasis to the lungs 
is 80% penetrant. Using the Cre/loxp system, I genetically labeled Tyr expressing 
cell subpopulations within the primary tumors with GFP in these mice and 
performed lineage tracing of the labeled cells. I hypothesized that the primary 
tumor derived Tyr expressing cells or their progeny can reach the lung and 
successfully seed metastases indicating the tumor-initiating capacities of the 
differentiated melanoma cell subpopulation. 
Question 2:  When do the metastatic melanoma cells start to disseminate 
into the circulation system? 
My aim was to identify the metastasis-initiating capacities of the primary 
tumor derived Tyr expressing cells. Experimental mice were monitored for 
several months after primary tumor formation. Given the variability in the timing 
of primary tumor and lung metastasis formation, I could not establish the exact 
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time of arrival of metastatic cells in the lung. Instead, I focused on the timing of 
metastatic cell intravasation. I labeled Tyr expressing cells in the mice at three 
different stages during tumor progression: pre-nevus stage, nevus stage and 
mature tumor stage. I hypothesized that Tyr expressing cells can invade blood 
vessels even before the appearance of any noticeable nevus. 
Question 3: What are the phenotypic changes that cells undergo during the 
process of metastasis? 
The GFP+ metastatic cells are derived from Tyr expressing cells inside the 
primary tumors. As the cells leave the primary tumors and enter the circulatory 
system, I hypothesized that the gene expression profile and pigmentation levels 
of those cells may undergo a reversible switch to facilitate metastasis. I used 
immunofluorescence staining with various markers to characterize the phenotype 
of metastatic cells associated with the pulmonary vasculature. 
Question 4: What are the putative mechanisms underlying melanoma 
metastasis? 
The GFP+ cells found in the lung were mostly associated with the vascular 
endothelium with an elongated shape. The mechanism and functional 
significance underlying the association between metastatic melanoma cells and 
vascular endothelial cells is not clear. I performed immunofluorescence staining 
of intravascular metastatic melanoma cells with endothelial cell specific markers 
and hypothesized that melanoma-endothelial transition in the primary tumors and 
endothelial-mesenchymal transition (EndMT) in the metastatic site are 
mechanisms underlying melanoma metastasis in the Dct-Grm1/K5-Edn3 mice. 
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Figure 1.1 Diagram of cancer metastasis. 
In primary tumors, angiogenesis, vessel co-option, VM and mosaic vessels are 
potential mechanisms underlying tumor vasculature. The vasculature in primary 
tumors not only provides oxygen and nutrients for tumor growth, but also 
provides a potential route for tumor dissemination. Metastatic tumor cells enter 
the circulation system as single CTCs or clusters through intravasation or other 
dissemination pathways or migrate along the abluminal vascular surfaces to 
nearby or distant sites as EVMM. CTCs arrest at the vascular endothelium in the 
metastatic organs and establish interactions with endothelial cells, roll along the 
endothelium to find the best sites for extravasation. Extravasated tumor cells 
proliferate and grow using angiogenesis or vessel co-option. EVMM is another 
potential source for metastases formation. Intravascular growth of metastatic 
cells in the microvessels with subsequent extravasation when intravascular 
micro-metastatic foci outgrow the vessels they are in can be another source. 
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Figure 1.2 Identification of metastatic cell populations in melanoma. 
Cells with varying differentiation levels are indicated by different colors in melanoma primary tumors. Certain 
melanoma cells can leave the primary tumor, enter the circulation system and reach the distal organs to seed 
metastases. The cell subpopulations that initiate melanoma distant metastases are still unclear and the phenotypic 
plasticity of the metastatic cell populations will be under investigation.
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2.1 Introduction 
Tumors are heterogeneous, involving not only the differences between 
various solid tumors but also between cell subpopulations within the same tumor. 
One of the important aspects of tumor heterogeneity that has recently gained 
increasing acceptance is the cancer stem cell model [1-3]. When it was first 
introduced in studies of human myeloid leukemia, it proposed that tumors are 
comprised of phenotypically diverse populations of cells, with only a rare, 
phenotypically distinct subset of cells having the capacity to significantly 
proliferate and form new tumors, while the bulk of cells within the tumor lose the 
tumorigenic capacity [4]. The cancer stem cell hypothesis has been extended to 
a great array of solid tumors. Using a model in which human breast cancer cells 
were grown in immunocompromised mice, Al-Hajj et al. showed that only a 
minority of breast cancer cells possessed the ability to form new tumors. Using 
the cell surface markers CD44+CD24−/low expression, they were able to 
distinguish the tumorigenic from the non-tumorigenic cancer cells within the 
breast cancer bulk [5]. Later, Singh et al. demonstrated that only the CD133+ 
brain tumor fraction contained cells capable of tumor initiation in NOD-SCID 
mouse brains and injection of as few as 100 CD133+ cells produced a tumor that 
could be serially transplanted and re-establish the heterogeneity of the parental 
tumor, whereas injection of 105 CD133- cells did not produce a tumor [6]. A 
similar study was carried out on prostate cancer. On the basis of the high surface 
expression of integrin 21 and CD133, the authors reported the identification 
and characterization of a subset of cells from primary and metastatic prostate 
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tumors that had cancer stem cell characteristics, which was also able to 
regenerate the phenotypically mixed populations of nonclonogenic cells [7]. In a  
study of human colorectal cancer, O’Brien et al. identified a human colon-
initiating cell subpopulation that was able to maintain themselves as well as 
differentiate and reestablish tumor heterogeneity upon serial transplantation 
using CD133 expression [8]. Subsequently, Dalerba et al. provided a more 
extensive surface marker profile, which better supported the tumor heterogeneity 
hypothesis, highlighting the epithelial cell adhesion molecule (EpCAM), also 
known as epithelial-specific antigen (ESA), and CD44 as more robust markers for 
colorectal cancer stem cells when compared to the previously reported marker 
CD133 [9]. Another study using a xenograft model identified a highly tumorigenic 
subpopulation of pancreatic cancer cells expressing the cell surface markers 
CD44, CD24, and ESA [10]. Using a similar approach as that for studies on 
breast cancer, Prince et al. identified a subpopulation of cells with cancer stem 
cell properties in head and neck squamous cell carcinoma (HNSSC), which were 
CD44+ and typically comprised <10% of the cells in a HNSCC tumor [11]. 
The cancer stem cell model has also been proposed for  melanoma [12] 
and several melanoma stem cell markers such as Nestin [13], CD133 [14, 15], 
CD271(also p75NTR) [16, 17], and JARID1B [18, 19] were demonstrated to 
select a subpopulation of melanoma cells with a higher tumor initiating capacity. 
However, the cancer stem cell model remains controversial in the melanoma field 
and several questions are still unanswered. For example, are the cancer stem 
cells a constant cell population within the hierarchically organized tumor? Or 
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does reversible phenotypic plasticity exist among these markers? Quintana et al. 
[20] pointed out that the frequency of tumorigenic melanoma cells that can be 
detected after xenotransplantation was highly assay-dependent. By making a 
series of changes in assay conditions, they increased the detectable frequency of 
tumorigenic melanoma cells after xenotransplantation into NOD/SCID IL2Rgnull 
(NSG) mice, proving that both CD133+ and CD133- fractions formed tumors that 
exhibited similar heterogeneity in CD133 expression. In a subsequent  study [21] 
by the same group, neither ABCB5 nor CD271 expression defined a 
subpopulation of cells that had enriched tumorigenic potential since all injections 
formed tumors that were phenotypically similar to the parent tumors irrespective 
of whether the cells injected were marker positive or negative. Additionally, both 
CD271+ and CD271- cells formed tumors capable of metastasis. Combined, the 
results of Quintana et al. led them to the conclusion that tumorigenic cells 
appeared to undergo reversible changes in the expression of many markers in 
vivo. This conclusion is further supported by the study of Roesch et al. [19] 
demonstrating that the JARID1B phenotype was dynamic, in that JARID1B-
negative cells also gave rise to a heterogeneous progeny containing JARID1B-
positive cells, which suggested a new understanding of melanoma heterogeneity 
with tumor maintenance as a dynamic process mediated by a temporarily distinct 
subpopulation. 
Overall, the two key components in the cancer stem cell scenario, the 
rarity and tumor initiating capacity, are still being questioned [22-24]. 
Xenotransplantation experiments were the basis to enrich tumorigenic cells from 
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non-tumorigenic cells in most of the cancer stem cell studies. Though widely 
used, as human tumor cells are being processed and transplanted, they are 
subjected to new environmental conditions that may alter their phenotype and 
consequently their tumor initiating capabilities [25]. Any of the conditions, such as 
the enzymatic dissociation conditions for human cells, mouse injection sites, the 
use of immunocompromised mice, as well as the patient’s stage of disease can 
contribute to conflicting results. Civenni et al. [16] developed a protocol to avoid 
trypsin during melanoma cell fraction preparation and the results obtained were 
compatible with those of some earlier studies. Their study provided some more 
convincing data given that the injected cells most likely did not lose surface 
marker expression because of interactions with digestive enzymes. Roesch et al. 
[19] compared the different effects of cell culture conditions and found that 
human embryonic stem cell medium better supported the survival of cells with 
inherent self-renewal potential when compared with conventional culture 
conditions. The optimized xenotransplantation assay with a more highly 
immunocompromised NOD/SCID IL2Rγnull mice  increased the detection of 
tumorigenic melanoma cells, demonstrating that tumorigenic cells are common in 
some human cancers [20]. Furthermore, certain cancer cell subpopulations were 
shown to have reversible drug-tolerance capacity and lose their stem cell 
markers during this process [26]. It is thus reasonable to speculate that the 
injection of cells obtained from patients that have undergone particular medical 
treatments may result in the generation of stem cell marker negative cells with 
tumorigenic capacity. 
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Because of the complexity of the metastatic process and the conflicting 
results obtained from injection and xenotransplantation studies, I propose that 
the direct in vivo lineage tracing of tumorigenic cells in a spontaneous mouse 
model of melanoma is a more robust and powerful tool to understand how 
specific subpopulations of cells within a tumor acquire highly invasive properties 
and is responsible for the seeding of distant lesions. My study will provide 
significant value to the understanding of melanoma metastasis and offer new 
venues for therapy development of melanoma patients. 
The use of lineage tracing in the cancer field has become more popular in 
recent years emphasizing the tracing of all progeny of one single cell. The basic 
foundations of lineage tracing and how data obtained from lineage tracing can be 
interpreted is reviewed by Blanpain and Simons with the focus on epithelial 
tissues [27]. Lineage tracing by genetic labeling is widely used for cell fate 
determination of stem and progenitor cells in the field of developmental biology, 
tissue maintenance and repair, and dynamics of tumor initiating capability of 
cancer cells. Shin and colleagues did fate mapping of Sonic hedhehog (Shh) 
expressing basal cells of the urothelium by lineage tracing and showed that Shh 
expressing cells can function as stem cells capable of generating all cell types to 
help maintain the epithelial integrity upon bacterial infection or chemical injury 
[28]. Another epithelial stem cell lineage tracing study performed in the murine 
small intestine showed that B lymphoma Mo-MLV insertion region 1 homolog 
(Bmi1)-expressing cells act as an alternative stem cell pool after the ablation of 
Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) expressing 
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stem cells [29]. In vivo lineage tracing and retracing by multicolor reporter mice 
gave the first strong evidence that Lgr5 expressing cells are stem cells in 
unperturbed primary tumors on a mouse model of intestinal adenomas [30]. A 
more recent clonal analysis using multicolor lineage tracing system on intestinal 
tumors further demonstrated the cancer stem cell role of Bmi1 and Lgr5 
expressing cells during tumor propagation [31]. Another good example for 
lineage tracing was carried out by Zhu and colleagues on high grade brain 
tumors [32]. This study gave direct evidence that Tlx is a brain tumor stem cell 
marker in a mouse model using RCAS/tv-a system [33] for tumor induction and 
Cre/loxp system for in vivo lineage tracing. Although lineage tracing has been 
widely used in different fields and certain kinds of tumors, there is a substantial 
gap in the field of melanoma biology and little is known about the cellular origin of 
melanoma, especially in identification of the precursor cells of metastasis. This is 
most likely the result of the lack of a good metastatic melanoma mouse model 
that can be used together with Cre/loxp system. In contrast, lineage tracing of 
stromal or endothelial cells during melanoma formation is easier since melanoma 
tumors can be obtained through tumor engraftment and transgenic mice with 
stromal or endothelial cells labeled are available. A recent quantitative clonal 
analysis using multicolor lineage tracing by Corey et.al [34] showed that in an 
elaborate tumor microenvironment created by the injection of the murine 
melanoma cell line B16F10, blood vessels followed a pattern of dynamic clonal 
evolution accompanied by the loss of lymphocyte adhesion molecules favoring 
the immune escape of cancer cells. The establishment of an in vivo lineage 
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tracing system to provide a detailed characterization of the cellular origin of 
melanoma metastasis is needed and will be of great significance both to the field 
of basic cancer research as well as to future clinical applications. 
2.2 Results 
2.2.1 Tumor Heterogeneity Exists in Mouse Melanoma 
To demonstrate cellular tumor heterogeneity in mouse melanoma, I 
studied the composition of tumors from Hepatocyte Growth Factor/Scatter Factor 
(HGF/SF) mice [35], Dct-Grm1/ K5-Edn3 mice and Dct-Grm1/K5-Edn3/Dct-Ednrb 
mice with spontaneously developed or UV induced lesions. Nestin [13], CD 271 
(also known as p75) [16, 17] were chosen as the stem cell markers and 
tyrosinase (TYR) or tyrosinase related protein 1 (TRP1) were used as 
differentiation cell markers. All the three melanoma tumors showed cellular 
heterogeneity with non-overlapping cell subpopulations positive for various 
markers (Figure 2.1). 
2.2.2 Mouse Model and Methodology Validation 
The Dct-Grm1/ K5-Edn3 mice were created in our laboratory [36, 37]. 
Depending on the aberrant expression of glutamate metabotropic receptor 1 in 
melanocytes and environmental Endothelin 3 (Edn3) expressed by keratinocytes, 
these mice not only spontaneously develop melanoma tumors on the ear, tail and 
dorsal skin, but also show metastases in the lung (Figure 2.2).  Chin et al. 
previously showed that Edn3 signaling promotes melanoma progression in Dct-
Grm1/ K5-Edn3 mice resulting in 80% penetrant lung metastases compared with 
the Dct-Grm1 controls that have limited metastatic capability [38]. On the basis of 
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the tumor heterogeneity scenario, this spontaneous mouse model of melanoma 
metastasis will be an ideal system to identify the intrinsic tumor initiating capacity 
of certain cell subpopulations within an unperturbed tumor environment. Given 
that the Nestin positive melanoma stem cells are rare in these tumors (Figure 
2.1), the differentiated Tyr expressing cells which constitute the majority of the 
tumor is a better option for lineage tracing. Tyrosinase is a copper-containing 
enzyme that catalyzes the production of melanin and the substrates give the 
color of skin, hair and eyes. Tyr is expressed specifically in melanocytes, the 
pigment producing cells, and majority of melanoma cells.  
Lineage tracing was performed using the Cre/loxp system with TYR-
CreERT2/ mT/mG mice. Briefly, in the TYR-CreERT2/ mT/mG mice, prior to Cre 
recombination, cell membrane-localized tdTomato (mT) fluorescence is 
expressed in every single cell. After tamoxifen/4HT induction, Tyr positive Cre 
recombinase expressing cells (and future cell lineages derived from these cells) 
show cell membrane-localized GFP (mG) fluorescence expression replacing the 
red fluorescence (Figure 2.3A). In vivo lineage tracing of Tyr expressing cells in 
the primary tumors can be performed on Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ 
mT/mG mice by topical 4HT application using a small painting brush on the 
primary tumor sites (Figure 2.3B). 
The Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice obtained from the 
mating of Dct-Grm1/ K5-Edn3 melanoma mice and TYR-CreRT2/ mT/mG mice 
spontaneously develop primary and metastatic melanomas, and Cre inducible 
Tyr positive cells that can be labeled with GFP making them distinguishable from 
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the other red fluorescent labeled cells in the body. Because these mice were 
obtained through breeding of several transgenic mice, the copy numbers of 
transgenes essential for tumor development were dramatically diluted resulting in 
a considerable delay in tumor appearance when compared to what was initially 
reported in Chin, 2015 [38]. In Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, 
the first primary tumors appeared at an average of 7.5 month (n=25), which is 2.5 
month longer than previously reported for the Dct-Grm1/ K5-Edn3 mice. 
To validate the topical application methodology, dorsal skin of the TYR-
CreERT2/ mT/mG mice was topically painted and successful GFP labeling of 
melanocytes in the hair follicles was observed, while other cells in the skin 
retained the tdTomato red fluorescence color (Figure 2.3C). The same induction 
method was applied to K5-Edn3/ TYR-CreERT2/ mT/mG mice, in which 
accumulation of melanocytes outside the hair follicles at the dermal-epidermal 
junction was expected [36]. Indeed, GFP+ green cells were found outside the 
hair follicles (Figure 2.3D). To establish if the TYR promoter can also drive Tyr 
expression in melanoma tumors in Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG 
mice, topical painting of 4HT was performed on the tail tumors of Dct-Grm1/ K5-
Edn3/ TYR-CreERT2/ mT/mG mice. A mutually exclusive pattern of GFP and 
tdTomato colors was found inside the tumors (Figure 2.3E). 
2.2.3 Labeling of the Tyr Expressing Cells in the Primary Tumors 
At an average of 7.5 month of age when the lesion first appeared as a 
nevus (<1mm in height) on the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, 
I started 4HT topical administration. 4HT induction exclusively at an early stage 
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was not sufficient to label the majority of Tyr expressing cells in the primary 
tumors (Figure S1). To ensure the labeling of most Tyr expressing cells in the 
primary tumors, 4HT topical administration was repeated for 3~4 weeks during 
tumor growth until euthanasia. Numerous GFP+ cells were detected in 
cryosections of primary tumors and lung metastases (Figure 2.4). To establish if 
the GFP+ cells in the primary tumors expressed Tyr protein, cryosections of the 
tumor were prepared soon after 4HT application and labeled with Tyr antibody. 
GFP+ cells were found to be positive for Tyr immunoreactivity (data not shown). 
2.2.4 Primary Tumor Derived Tyr Expressing Cells or Their Progeny Can 
Reach the Lung and Seed Metastasis 
The appearance of metastases in distant organs was established 2 weeks 
to 7 months after the first 4HT painting of primary tumors. Micro-metastases, 
characterized as clusters of less than 10 cells, were detected in 86% of lungs 
examined (n=15). Each lung was sectioned and at least 20 cryosections per lung 
were examined for the presence of primary tumor derived GFP+ cells. In 50% of 
4HT painted Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, GFP+ cells were 
identified in various areas of the lung and other organs (Table S1). The number 
of GFP+ cells found in the lung varied considerably, from 2 to 20 or more cells 
per section. In most mice, the numbers were low, except for one mouse that 
presented with pepper like micro-metastases and another one with macro-
metastases. No GFP+ cells were found in lungs of control mice (Dct-Grm1/ K5-
Edn3/ mT/mG) that had tumors painted with 4HT (n=10). Additionally, no GFP+ 
cells were detected in the lungs of mice that did not bear tumors (Dct-Grm1/ K5-
 42 
Edn3/ TYR-CreERT2/ mT/mG) and had their dorsum painted with 4HT (n=3). The 
location of the primary tumor affected the penetrance of GFP+ cells in the lung of 
4HT painted Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice (Table S1). Only 
one out of seven mice (1/7, 14%) that had only tail tumors painted, in contrast to 
three out of four (3/4, 75%) mice that had only dorsal tumor painted, presented 
with GFP+ cells in the lung. The only mouse with a dorsal tumor that did not have 
GFP+ cells in the lung was painted only once at the nevus stage and no obvious 
tumor growth was observed upon euthanasia.  
The GFP+ cells were distributed into three categories depending on their 
location in the lungs.  The first category termed “inside the vessels” includes 
intravascular solitary cells with an elongated and spindle shape found in close 
association with the endothelial layer of the lung vasculature (Figure 2.5A). Cells 
in this category were detected consistently, even on metastasis-free lungs, 
providing support to the hematogenous dissemination of metastatic cells. The 
second category termed “outside the vessels” consists of clusters of GFP+ cells 
overlapping with the pigmented metastases (Figure 2.5B) with the possibility that 
some may be still inside the alveolar capillaries. The rarest third category 
consisted of solitary or tiny clusters (2~5) of cells outside the vasculature 
displaying no pigmentation. Immunostaining showed that the GFP+ cell 
populated metastatic lesions in the lung were positive for melanoma markers 
TYR and TRP1 (Figure 2.5C, D), indicating the tumor initiating capacity of the 
differentiated Tyr expressing cells or their progeny in the Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mice. Of note, not all metastatic lesions in the lung 
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contained GFP+ cells. This finding was not unexpected given that the efficiency 
of the topical 4HT induction is not 100%, and that, primary tumor resident Tyr 
negative cells might also metastasize.  
2.2.5 Presence of Metastatic Cells inside the Lung Vasculature 
Melanoma metastasis has been suggested as an inefficient process, 
during which only a small number of cells can go through all the steps for a 
clinically significant metastasis [39, 40]. It has been generally thought that most 
metastatic cells are eliminated in the circulation [41]. In a small number of 
animals (n=4) that were not subjected to cardiac PBS perfusion, lungs were snap 
frozen immediately after euthanasia. In sections of these lungs, the blood vessels 
were filled with blood but very few circulating GFP+ cells were found inside the 
lumen of the vasculature (Figure S2E). Instead, we observed large numbers of 
metastatic GFP+ cells associated with the pulmonary vascular endothelium or 
invading the lung tissue. The number of GFP+ cells “inside the vessels” far 
exceeded the micro- or macro-metastatic lesions “outside the vessels”. To find 
out if GFP+ cells were proliferating, we performed Ki67 staining on the lung 
sections where GFP+ cells were found. Double labeled GFP and Ki67 cells were 
mostly confined to cell clusters “outside the vessels” (Figure 2.6E-H). In contrast, 
the solitary GFP+ cells “inside the vessels” were mostly Ki67 negative, although 
some Ki67+ cells were identified (Figure 2.6A-D). In the lungs of Dct-Grm1/ K5-
Edn3/ TYR-CreERT2/ mT/mG mice (n=3), the percentage of Ki67+ intravascular 
GFP+ cells was less than 1% (Figure 2.7A). Disseminated cancer cells within the 
circulation are exposed to the mechanical sheer stress, as well as immune 
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surveillance, which may lead to rapid cell death [40, 42]. Most of the GFP+ cells 
were found inside the vasculature including the big pulmonary arteries. To 
determine if GFP+ cells had undergone apoptosis, we performed immunostaining 
with an antibody against Cleaved Caspase 3. We were only able to detect a 
small number of double labeled GFP + and Cleaved Caspase 3 + cells “inside 
the vessels” (Figure S3). In the lungs of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ 
mT/mG mice (n=3), the percentage of Caspase 3+ intravascular GFP+ cells was 
less than 3% (Figure 2.7B). 
2.2.6 Presence of Perivascular Cellular Infiltrates in Metastatic Lungs 
The detailed examination of lung cryosections of Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mice where GFP+ cells were found, indicated the 
presence of perivascular infiltrates in close proximity to the GFP+ cells. Notably, 
the infiltrates were more obvious in lungs with micro-metastases (n=5) compared 
with that with macro-metastases (n=2). Hematoxylin-eosin (H&E) staining 
showed abnormal aggregates of cells surrounding the pulmonary vasculature, 
among which brown pigmented macrophages were noticed (Figure 2.8A, B). 
Small to no infiltrates were observed in GFP+ cell-free lungs. Fluorescence 
immunostaining of the lung cryosections showed that the infiltrates were mostly 
composed of CD45+ lymphocytes (Figure 2.8C), including CD3 positive T cells 
(Figure 2.8D). Most cells within the infiltrates showed high levels of proliferation 
as demonstrated by Ki67 immunoreactivity (Figure S4), suggesting the activation 
of an immune response to the arrival of GFP+ metastatic cancer cells inside the 
vasculature. These abnormal perivascular infiltrates found in lungs containing 
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foreign GFP+ cells may add another explanation for the dormancy of 
intravascular cancer cells. 
2.2.7 GFP+ cells Lose Pigmentation upon Contact with Vascular 
Endothelium 
In order to detect any changes in the differentiation status of metastatic 
cells, the pigmentation level of GFP+ cells was monitored as cells traveled from 
the primary tumor to the lungs. At the primary tumor site, tissues deep 
underneath the skin tumors containing blood vessels were collected and 
sectioned. GFP+ cells were identified both inside and outside the vasculature 
and interestingly, GFP+ cells inside the vasculature were not pigmented (Figure 
2.9A, D, arrowhead) while GFP+ cells outside the vasculature were pigmented 
(Figure 2.9A, D, arrow). This same dynamic pattern of pigmentation levels was 
observed in the lung.  Intravascular GFP+ cells in the lung vasculature were not 
pigmented (Figure 2.9B, E, arrowhead), but resumed pigmentation production 
while populating the lung metastases (Figure 2.9C, F, arrow). 
2.2.8 Characterization of Metastatic GFP+ Cells Inside Pulmonary 
Vasculature 
Given the loss of pigmentation by GFP+ cells as they entered the 
vasculature, further characterization was necessary to establish their level of 
differentiation. Immunostaining was performed on the lung cryosections with the 
neural crest specific marker SOX10 (Figure 2.10A-D) and differentiated 
melanocyte markers TYR and TRP1 (Figure 2. 10E-L). The GFP+ cells were 
negative for all of them. The testing of other melanocytic lineage markers such as 
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MITF and TRP2 also yielded negative results (data not shown). Based on the 
stem cell model, it is possible that the differentiated Tyr expressing cells or their 
progeny de-differentiated and transiently acquired stem cell properties. In 
previous studies, P75 and Nestin were shown to selectively label melanoma 
tumor initiating cells [13, 16, 17]. As such, we performed immunostaining with 
P75 and Nestin on the lung cryosections where GFP+ cells were found, and the 
results were also negative (Figure 2.10M-T). All fluorescence immunostaining 
was done with a positive control to validate the indicated antibodies used, and 
the staining results are representative of at least five mice. 
2.2.9 Primary Tumor Derived Tyr Expressing Cells or Their Progeny Can 
Reach other organs and Seed Metastasis 
Regional lymph node metastasis is regarded as an indicator of metastasis 
for many malignancies, including melanoma [43]. Although organ preferences of 
melanoma metastasis are observed, they can spread widely in the body. Most 
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice with tumors showed enlarged 
and hyperpigmented lymph nodes. Cervical lymph nodes were collected from 
4HT painted mice and examined for GFP+ cells. Fifty eight percent (7/12) of the 
mice with the presence of GFP+ cells in the lung also presented with GFP+ cells 
in the lymph nodes (Table S1 and Figure 2.11). The enlarged lymph nodes of 
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were rich with vessels 
(blood/lymphatic). The staining pattern of TYR in lymph nodes occupied by GFP+ 
cells was different from that in the lung. The GFP+ cells in lymph nodes were 
more heterogeneous, both TYR+ (Figure 2.11, arrowhead) and TYR- (Figure 
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2.11, arrow) GFP+ cells were found. Additionally, TYR+ cells that were not GFP+ 
were also observed (Figure 2.11, star) indicating either the insufficiency of 4HT 
topical induction or the presence of non-Tyr expressing cell subpopulations. 
The most common sites of visceral metastases in the Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mice were lungs, with only one mouse (1/15) showing 
evident kidney and spleen metastases. The GFP+ cells were found inside the 
metastatic foci of the kidney and spleen (Figure S2F-I), further demonstrating the 
tumor initiating potential of the primary tumor derived Tyr expressing cells or their 
progeny. 
The Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice spontaneously 
develop multiple melanocytic tumors on the skin, all of which were presumed as 
primary tumors. However, it is plausible that cells from the first dorsal/tail tumor 
spread and seeded the secondary dorsal/tail tumor at different sites of the 
dorsum/tail. In three Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, the dorsal 
tumors and only one tail tumor were subjected to topical 4HT painting. One tumor 
per mouse that appeared later and was not painted was checked for the 
presence of GFP+ cells. Interestingly, non-painted tumors from the three mice 
were mainly constituted by GFP+ cells (Figure S5). To exclude the inappropriate 
spread of 4HT from grooming behavior, the non-painted tumors examined were 
chosen as far as possible from the painted ones, for example, a non-painted tail 
tumor proximal to the body vs. a painted tail tumor distal to the body; a non-
painted dorsal tumor on top of right hind leg vs. a painted dorsal tumor on left 
flank. Although we could not establish whether the tumorigenic GFP+ cells giving 
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rise to the non-painted tumor were dorsal tumor-derived or tail tumor-derived, the 
result presented here further proved the tumor initiating capacity of Tyr 
expressing melanoma cells or their progeny. 
2.2.10 Metastatic Melanoma Cells Disseminate Early during 
Melanomagenesis 
Late recurrence is fatal and has been shown clinically in melanoma 
patients who have gone through primary tumor resection at early diagnosis. 
Although greater than 85% cutaneous melanoma patients can be cured after the 
removal of the primary tumors, a small number of patients may show recurrence 
as late as 15-20 years [44]. This not only indicates the existence of metastasis 
dormancy but also suggests that metastatic melanoma cells may disseminate 
into the circulation system much earlier than previously expected. To test this, we 
grouped the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice into three stages, 
before nevus stage (n=3, no noticeable nevus or tumor was observed), nevus 
stage (n=3, <1mm in height) and tumor stage (n=3). We painted 4HT on the 
nevus or tumor as described previously. For the before nevus stage group, 
painting of 4HT was performed 3-4cm from the end of the tail. The tails with the 
painted area were collected and sections containing blood vessels were 
analyzed for the presence of GFP+ cells. The GFP+ cells were found inside the 
tail vasculature at all three stages (Figure 2.12). The results indicate that 
tumorigenic cells acquire and maintain the ability to enter the circulation at all 
times during the process of tumorigenesis, even prior to the formation of a 
sizable tumor. 
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2.3 Discussion 
Melanoma, the deadliest type of skin cancer, still imposes a great 
challenge for therapy because of its highly aggressive nature to metastasize to 
distant organs. As an important step of preclinical research, some melanoma 
murine models have been developed, including xenograft, syngeneic, and 
genetically engineered models, to help understand the mechanisms of melanoma 
progression or develop promising therapies to melanoma patients. It is generally 
believed that genetically engineered models are better options compared with 
xenograft or syngeneic models in regard to anticancer drug assessment [45]. 
Among the genetically engineered melanoma mouse models that have been 
developed, some require extra carcinogens to induce melanoma, such as UV 
exposure, which adds to the cost and labor-intensive interbreeding of multiple 
mouse strains. More important, few of the genetically engineered melanoma 
mouse models were reported to develop visceral metastases, which limits the 
study of melanoma metastasis. Of the several melanoma mouse models that 
show distant metastasis, some of them already employed Cre/loxp to induce 
tumors, preventing us from using the Cre/loxp system for lineage tracing [46, 47]. 
The Dct-Grm1/ K5-Edn3 mice, to our knowledge, is the first spontaneous 
melanoma metastasis mouse model that is free of oncogenes and dependent 
exclusively on the presence of signaling pathways. The tumor metastasis 
process of these mice closely resembles that in human melanoma patients given 
the variability in time to tumor and appearance of metastasis. Although the Dct-
Grm1/ K5-Edn3 mice provide us with an optimum system for lineage tracing of 
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metastatic cells within an unperturbed tumor environment, the number of 
samples that can be obtained within a reasonable amount of time is limited. In 
the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice where lung metastases are 
identified, the terminal fate of those labeled cells in the secondary organ can be 
determined and perhaps more interesting, the dynamic changes in genotype and 
phenotype during the metastatic process can also be investigated.  
To spatially restrict Cre induction within the primary tumors, we topically 
applied 4HT on the tumors instead of systemic administration. 4-
hydroxytamoxifen topical application has been successfully used in other studies 
for site specific Cre induction [48-50]. The fact that GFP+ cells were absent in 
some lungs with pigmented metastases attests to the spatial restriction of Cre 
induction, given that all melanocytic lesions should be labeled with GFP if 
systemic administration of 4HT through blood happened. In addition, the absence 
of GFP+ cells in some pigmented lesions, but not others, in the same lung further 
excluded the possibility of 4HT systemic administration. In other words, GFP+ 
cells found in the lung can only be derived from the dorsal/tail tumor that were 
4HT painted. Although labeling of Tyr expressing cells may not be 100% efficient, 
this should not constitute a problem for this study considering the abundance of 
differentiated cells in the melanoma lesions. It is important to bear in mind that 
cancer is complex and dynamic. As tumors grow, they may recruit more 
melanocytes located in the dermal-epidermal junction, and it is also possible that 
stroma cells transdifferentiate into Tyr expressing melanocytes as it was shown 
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that a combination of three factors, MITF, SOX10 and PAX3, were sufficient to 
convert mouse and human fibroblasts to functional melanocytes in vitro [51].  
The heterogeneity of tumors including melanoma has been recognized for 
decades pointing to the varied tumor initiating capacities of cell subpopulations 
within the solid tumors [52]. While some studies have confirmed that cells that 
express melanoma stem cell markers have tumor initiating capacity, they have 
mostly focused on primary tumor formation not metastasis. The robustness of the 
stem cell markers used in these studies is also controversial based on the use of 
xenotransplantion assays [13-17]. Here, using Cre/loxp system, we genetically 
labeled Tyr expressing cells within the primary tumors in the Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mice and tracked the fate of the labeled cells by lineage 
tracing. We demonstrated that the more differentiated Tyr expressing cells can 
also be the progenitors of tumor initiating cells and seed distant metastases in 
various organs successfully in mice. However, what we have shown does not 
refute entirely the stem cell scenario in that gene expression profiles are dynamic, 
and it is possible that GFP+ cells de-differentiated to a more stem cell-like state 
after the labeling. This is also supported by the fact that GFP+ cells lost their 
pigmentation, as well as melanocytic lineage markers while in contact with the 
vascular endothelium, but, regained those features after seeding metastases. 
The fact that tumor cells are plastic increases the complexity of the 
melanomagenesis process, suggesting that the tumor initiating potential of 
melanoma cells may be underestimated and the spatial and timing elements 
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should be considered when a melanoma stem cell marker is defined or 
characterized. 
Metastasis disease is the primary cause of death in cancer patients. 
Although prolonged survival occurs as a result of the development of newr 
therapies and better understanding of the metastatic mechanism, the early 
diagnosis of cancer metastases has always been a challenge. In general, human 
tumor metastasis consists of a series of biological processes including: 
metastatic cells leave the primary tumor, invade into surrounding tissues and 
enter the blood or lymphatic vessels, travel through the circulatory system, arrest 
at the distant organs and finally seed successful metastases [53, 54]. Most 
studies on melanoma metastasis were either focused on the first stage (primary 
tumors) or the last stage (metastatic tumors). Gene microarray data from 
different stages of melanoma progression were analyzed and shed light on the 
mechanism of metastasis [55-58]. Metastatic tumor cells in circulation have been 
long recognized, and CTCs in the blood stream have been successfully isolated 
from human blood [59-61]. An FDA approved detection system, Cellsearch, is 
available for the isolation of CTCs and has been successfully used for monitoring 
patients with metastatic breast, prostate and colon cancers [62]. Nonetheless, no 
consensus has been reached regarding melanoma CTCs because of sample 
scarcity, cohort heterogeneity, and the application of Cellsearch on melanoma 
patients seems not sensitive enough and needs further investigations [63]. The 
development of real-time imaging techniques, such as non-invasive methods or 
intravital microscopy, make it possible to study the dynamic process of cancer 
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metastasis [64-66], including melanoma [67, 68]. However, real time imaging 
cannot investigate the genetic diversity of the metastatic tumor cells, and most in 
vivo real time imaging has been based on cell injection, xenograft or syngeneic 
transplantations, bypassing the complexity of endogenous tumor-host 
interactions. In our study the use of a spontaneous melanoma mouse model 
depending on GRM1 and Edn3 signaling pathways allowed us to characterize 
the dynamic gene expression profiles of metastatic cells in relationship to their 
spatial distribution during the journey from primary tumor sites to secondary 
organs and represents a tremendous advantage in understanding mechanisms 
associated with melanoma metastasis.  
It is noteworthy that the better studied CTCs are not necessarily the 
contributors of metastases or recurrence, instead, disseminating cells that 
survive after infiltrating distant organs, may be more dangerous since they can 
be dormant anywhere as invisible, undetectable solitary or cluster of cells. 
Studies about metastatic dormancy on a variety of cancers have been increasing 
[62, 64, 69], but little attention has been paid to metastatic dormancy of 
melanoma. During the discussion between members of the Melanoma Research 
Foundation (MRF) Scientific Advisory Council and Breakthrough Consortium in 
2015, Merlino et al. highlighted melanoma dormancy as one of the four thematic 
areas and raised the issue that study of melanoma dormancy lagged significantly 
behind that of breast and prostate cancers and research about this area was 
required [70]. 
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Although it has been proposed that metastatic dormancy of melanoma can 
be established directly at the target organ [70], in vivo evidence is missing. The 
best studied location of metastatic dormancy in cancers is the bone marrow [71-
73], as has been shown in the only melanoma dormancy study with the Ret 
transgenic mouse model [74].  The data presented in this study suggested that 
the vascular endothelium in the target organ can act as a potential reservoir for 
metastatic melanoma cell dormancy. We found that the primary tumor derived 
metastatic melanoma cells associated with the pulmonary vascular endothelium 
did not proliferate or undergo apoptosis, recapitulating the state of metastatic 
dormancy. As a consequence of the limitation of our model, identification of the 
fate of each individual cell is impossible, as such, we cannot conclude that the 
dormant melanoma cells inside the pulmonary vasculature are the ones that exit 
and seed the overt metastases after reactivation. The CTCs may also be 
possible contributors [75].  
Late recurrence of melanoma has been reported, and the recurrence site 
is commonly the lungs [76]. If the presence of putative dormant metastatic cells 
in the vasculature of the lung also occurs in human patients, stopping therapies 
in patients who are thought to be disease free may have dire consequences. The 
mechanism used by disseminated tumor cells to survive in immunocompetent 
individuals for an extended period of time is one of the biggest conundrums in 
tumor immunology. A possible explanation is what has been called tumor 
immunoediting: genetically and epigenetically unstable tumor cells can adapt to 
immune attack by either down regulating tumor associated antigens or shutting 
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down death signaling pathways [77]. The loss of the melanocytic/melanoma 
markers by the GFP+ cells may represent this concept of immunoediting. 
Although viable, the outgrowth of the dormant tumor cells is restrained by the 
adaptive immunity. Koebel et al. called this process “equilibrium” and they 
provided evidence that tumor cells in equilibrium were highly immunogenic 
whereas the outgrowing tumor cells were not [78]. This is in line with the results 
obtained with the Ret transgenic  mouse model where it was shown that  bone 
marrow melanoma-specific memory T Cells were detectable and functionally 
active in tumor free mice [74] and that CD8+ T cells could delay the visceral 
metastases in the mice [79, 80]. Stronger evidence of the tumor-immune 
“equilibrium” can be obtained from clinical reports of donor derived melanoma 
through transplantation surgeries [81-84]. In our study, the fact that lymphocytes 
in the perivascular infiltrates were found in the lungs where dormant melanoma 
cells were identified but not obvious in lungs with full-blown metastases can be 
explained by the immune equilibrium. Yet, further investigation is needed to 
elucidate the mechanisms underlying the interplay between immune cells and 
dormant metastatic cells. 
Early dissemination of abnormal cells has been detected in murine models 
of various cancers [85-89]. Numerous cases of patients with metastatic 
melanoma free of detectable primary tumors have been reported clinically [90-95]. 
The presence of GFP+ cells inside the vasculature at all stages during the 
process of tumorigenesis, even prior to the formation of a sizable tumor indicated 
the early dissemination of melanocytes. Although there is a high chance that 
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these intravascular GFP+ cells disseminating early into tail vasculature are just 
dormant and not fully malignant, this still constitutes strong evidence that 
prospective metastatic melanoma cells may enter the circulation system before 
the formation of primary tumors. The study showing untransformed mouse 
mammary cells in the circulation could acquire malignant growth upon oncogene 
activation further argued the possibility that untransformed cells that 
disseminated early could account for the later metastases [87]. 
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Figure 2.1 Heterogeneity of melanomas from different transgenic mice. 
A and B, HGF/SF mouse;  C and D, Dct-Grm1/K5-Edn3 mouse; E and F, Dct-
Grm1/K5-Edn3/Dct-Ednrb mouse.  A, C and E indicate Nestin and TRP1 
immunostaining of paraffin-sections. B, D and F indicate Nestin and P75 
immunostaining of paraffin-sections. Note the distinct cell subpopulations in the 
same solid tumor. 
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Figure 2.2 Mouse model of melanoma metastasis. 
Dct-Grm1/ K5-Edn3 mice spontaneously develop melanocytic lesions on the ear, 
tail and dorsal skin (A) and metastases in the lung (B). The pigmented lesion in 
the lung is positive for melanoma marker TRP1 (C is the bright field of D). 
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Figure 2.3 Mouse model of melanoma metastasis. 
Diagram shows how Cre/loxp system was used with mT/mG loxp reporter mice 
and TYR promoter/enhancer controlled Cre expression in TYR-CreERT2 mice (A). 
An in vivo lineage tracing system can be established on the progeny mice 
carrying all the transgenes from TYR-CreERT2/mT/mG and Dct-Grm1/ K5-Edn3 
mating. Instead of systemic administration, 4HT was topically applied to the 
primary tumor sites to exclusively label Tyr expressing cells inside the tumor, not 
the other sites. Lineage tracing of the GFP+ cells during melanoma metastasis is 
achievable (B). 4HT topical application was validated on both TYR-CreERT2/ 
mT/mG mice, where melanocytes are located inside hair follicles (C, arrow), and 
K5-Edn3/ TYR-CreERT2/ mT/mG mice, where melanocytes outside the hair 
follicles are also expected due to the abundant Edn 3 in the environment (D, 
arrow). This methodology was also valid in the melanoma mouse model Dct-
Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG. 4HT painted tail tumor cryosections 
were directly visualized under fluorescent microscope. Numerous green cells 
were found inside the tumor, consistent with the abundance of Tyr expressing 
differentiated cells in melanoma (E). Green, GFP+ melanocytes; Red, tdTomato, 
expressed in all non-recombined cells; Blue, nuclei counterstained with DAPI. 
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Figure 2.4 Labeling of the Tyr expressing cells in the primary tumors. 
4HT was topically painted on the dorsal (A) or tail tumors of Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mice, lung metastases with pigmentation were found after 
the mice were euthanized(C). Cryosections of the dorsal tumor were directly 
visualized under the fluorescence microscope and numerous GFP+ cells were 
found (B). 
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Figure 2.5 Lineage tracing of tumorigenic cells to the lung. 
GFP+ cells were found in the lung, most of which were located at the inner wall 
of vasculature as single cells with an elongated, spindle shape (A), clusters of 
green cells were mainly seen in the lung metastatic foci (B, insert: bright field of 
the boxed area, showing green cells overlapped with pigment). GFP+ cell 
populated metastases in the lung were TYR and TRP1 positive showing the 
successful seeding of melanoma metastases (C, D). 
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Figure 2.6 Primary tumor derived GFP+ cells proliferated in the lung. 
Top panel (A-D) showed one GFP+ cell located at the inner layer of the lung blood vessel (the green cell was 
located at the longitudinal section part of the vasculature) was positive for Ki67. Lower panel (E-H) showed one 
GFP cell inside the pigmented micro-metastasis expressed Ki67. Red, Ki67; green, GFP from the Cre induction or 
anti-GFP antibody used to amplify the signal for immunostaining; blue, DAPI. 
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Figure 2.7 Numbers of Ki67 or Caspase3 staining of intravascular GFP+ cells in 
the lung. 
Less than 1% Ki67+ and less than 3% Caspase3+ intravascular GFP+ cells were 
identified in the lung of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. 
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Figure 2.8 The presence of GFP+ cells in the lung was associated with 
perivascular infiltrates. 
Hematoxylin-eosin (H&E) staining (A, B) of lung cryosections from Dct-Grm1/ K5-
Edn3/ TYR-CreERT2/ mT/mG mice, of which primary tumor derived GFP+ cells 
were found. Perivascular cellular infiltrates were shown in the lung. B, a higher 
magnification of the cellular infiltrates, brown pigmented macrophages were seen 
inside the infiltrates. Immunostaining with indicated markers showed the 
perivascular infiltrates were mostly CD45 (lymphocyte common antigen) positive 
(C), and some were T cell marker CD3 positive (D). Note, one GFP+ cell was 
shown inside the vessels in C and D. 
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Figure 2.9 Pigmentation level of GFP+ cells during metastasis. 
GFP+ cells lost pigmentation while they were inside the vasculature at the tail 
tumor site (A, D, arrowhead) and in the lung (B, E, arrowhead), but produced 
pigmentation when they were outside the vessels (A, D, arrow) or within the 
metastatic foci (C, F, arrows). D-F are bright fields of A-C, respectively. 
Cryosections were counterstained with DAPI. 
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Figure 2.10 Immunostaining of GFP+ cells in the lung vasculature of Dct-Grm1/ 
K5-Edn3/Tyr-CreERT2/mT/mG mice. 
GFP+ cells in contact with lung vasculature (A, E, I, M, Q) did not express Sox10, 
TYR, TRP1 (B, F, J), P75, Nestin (N, R). Staining was performed on cryosections 
with appropriate positive controls to validate the indicated antibodies.
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Figure 2.11 Characterization of GFP+ cells in lymph nodes. 
TYR staining was done on the lymph node cryosections where GFP+ cells were found. Some GFP+ cells inside the 
lymph nodes expressed TYR (arrowhead), while some did not (arrow). A-D, a lower magnification; E-H, a higher 
magnification showed GFP+ cells inside the vasculature. Some TYR positive cells are not GFP+ (star). 
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Figure 2.12 Timing of metastatic GFP+ cell dissemination. 
4HT was painted on nevus or tumor or normal skin of the tail. Cryosections of the tail with the painted area were 
immunostained with CD31 to localize blood vessels underneath the tail skin. GFP+ cells were found inside the tail 
vasculature at all three stages. GFP, green; CD31, red; DAPI, blue. Only the vasculature underneath the painted 
area is shown, not the actual nevus/tumor/skin.
 77 
 
CHAPTER 
 
3. PHENOTYPIC PLASTICITY OF METASTATIC MELANOMA 
CELLS 
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3.1 Introduction 
The vasculature plays an essential role in cancer progression. Most 
studies that have implicated the vasculature as a key factor in tumorigenesis 
have focused on the process of angiogenesis [1]. However, there is some 
evidence that angiogenesis may not be required for metastasis and other 
mechanisms such as vessel co-option have been suggested as an alternative [2]. 
In vessel co-option, tumor cells hijack and migrate along preexisting vessels of 
the host organs. Vessel co-option has been observed in human primary tumors 
and metastases and is most frequently described in highly vascularized tissues 
such as brain, lung, and liver [2]. Vessel co-option was detected in melanoma, 
and proposed to be the process employed by tumors to continue growing after 
antiangiogenic therapies [3, 4]. 
Another alternative pattern of tumorigenic functional microcirculation that 
has received special attention is VM where tumor cells acquire the capacity to 
form endothelial-like vessels recapitulating embryonic vasculogenesis. 
Vasculogenic mimicry is a striking example of tumor plasticity where tumor cells 
can transdifferentiate into an endothelial-like phenotype and express vascular 
related molecules. Numerous VM studies in distinct cancers have been published 
since the first introduction of this concept in 1999 [5, 6]. Vasculogenic mimicry 
was first described in the context of human melanoma cells [6] and originally 
defined as the ability of aggressive melanoma cells to form CD31 negative but 
Periodic acid schiff positive vascular-like networks. Periodic acid schiff stains 
basement membranes including laminin, collage and glycogen and CD31 is an 
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endothelial cell specific marker. Later, the same group provided the first direct 
evidence that another endothelial-associated molecule, vascular endothelial 
(VE)-cadherin, was exclusively expressed by highly aggressive melanoma cells 
and dispensable for VM [7]. Signaling pathways underlying VM with a focus on 
VE-cadherin expression were recently reviewed [8]. Although absence of CD31 
is a characteristic of VM in melanoma, CD31 expression was reported in VM 
capable cell lines from ovarian cancer [9], prostatic cancer [10] and breast cancer 
[11]. Distinct contributions of VE-cadherin and CD31 in vessel formation [12] and 
embryonic origins of the tumor cell types may provide some clues to the selective 
expression of these two genes, but further investigations are needed to elucidate 
their specific roles in VM [13]. 
Tumor cells in various cancers, including melanoma, that are capable of 
VM share the “stemness” feature [14-19]. Gene-expression profiling of more than 
45 human cutaneous and uveal melanoma-cell lines showed that, compared with 
the poorly aggressive melanoma cells, highly aggressive melanoma cells down-
regulated melanoma-specific markers including MITF, TYR, TRP1 and 
upregulated angiogenesis and vasculogenesis genes such as VE-cadherin, 
erythropoietin-producing hepatocellular carcinoma-A2 (EPHA2), and laminin 5 
γ2-chain (LAMC2) [13]. The interplay between tumor cells acquiring endothelial-
like and stem cell-like features may be what allows VM to participate in tumor 
metastasis or recurrence. The functional significance of VM is not well 
understood, but it may be involved in facilitating tumor perfusion and 
dissemination. Vasculogenic mimicry is positively related with tumor 
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aggressiveness and an overall shorter survival time [20-22]. Vascular 
endothelial-cadherin positive melanoma cells co-expressing the stem cell marker 
CD133 engaged in VM creating a perivascular niche essential for primary tumor 
growth in mouse xenografts [19]. Another study by Wagenblast et al., linked VM 
in primary tumors with distant metastases in a breast cancer tumor mouse model. 
They provided evidence that Serpine2 and Slpi not only played essential roles for 
VM, but, as anticoagulants, also promoted metastatic cell intravasation and 
ultimate metastases by maintaining perfusion of the tumor cell-lined networks at 
the vascular/extravascular interface [23]. 
Another special pattern of vasculature in tumors is mosaic vessels, where 
vessels contain both authentic endothelial cells and tumor cells. Mosaic vessels 
in tumors were first observed in colon carcinoma, featured by discontinuous 
endothelial marker CD31 expression in tumors [24]. Mosaic vessels in 
hepatocellular carcinoma were also reported [25]. One of the proposed potential 
mechanisms of mosaic vessel formation [26] lies in the plasticity of highly 
malignant tumor cells, suggesting tumor cells can mimic the endothelial cells thus 
displace endothelial cells of the vessel lining. Whereas mosaic vessel features 
the endothelial-like behavior of cancer cells, those cancer cells being part of the 
vasculature do not express the typical endothelial cell marker CD31. 
Vessel co-option differs from VM and mosaic vessels in that it is a non-
angiogenesis mechanism. Tumorigenic cells take advantage of the preexisting 
vasculature for tumor growth or migration. While vessel co-option has not been 
associated to the process of angiogenesis, VM and mosaic vessels have been 
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studied within its context. All studies about VM and mosaic vessels were carried 
out to demonstrate their relevance for primary tumor outgrowth and no 
correlation to the metastatic process has been established. Although some 
authors have hypothesized a functional role for VM and vessel co-option in 
facilitating tumor cell dissemination, no direct evidence is available. In the 
present study, I show a novel tumor-vasculature pattern observed in a 
spontaneous melanoma mouse model. In the new pattern, melanoma metastatic 
cells transdifferentiate into endothelial cells, hijack the existing vasculature at the 
metastatic sites and assemble an intravascular niche. I propose that in this niche 
metastatic cells are allowed to survive as dormant cells and re-acquire metastatic 
properties for latent spread.  
3.2 Results 
3.2.1 Vascular Endothelium Associated GFP+ Cells Express Endothelial 
Cell Markers 
In the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, most metastatic 
GFP+ cells in the lung were located inside the pulmonary vasculature. To 
establish the exact intravascular location of GFP+ cells in the lung, we labeled 
the lung cryosections where GFP+ cells were found with an antibody against 
CD31 to identify the vascular endothelial cells. To our surprise, the average of 
intravascular GFP+ cells was CD31 staining was also observed in approximately 
70% of the GFP+ cells associated with the vascular endothelium (Figure 3.1, top 
panel), including solitary GFP+ cells in alveolar capillaries (Figure S6). To further 
confirm the acquisition of an endothelial phenotype by the GFP+ cells, we used 
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another endothelial cell marker, VE-cadherin, a similar percentage of 
intravascular GFP+ cells also labeled with VE-cadherin demonstrating their 
endothelial nature (Figure3.1, bottom panel). 
Since CD31 and VE-cadherin are expressed in the membrane at the cell-
cell junction it is plausible that the staining detected was in fact associated with 
the vascular endothelial cells surrounding the GFP+ cells. In order to fully 
establish which cell type was immunolabeled with the antibodies against CD31 
and VE-cadherin, small segments (2-3mm length) of pulmonary artery, 
pulmonary vein and aorta were obtained from 4HT painted mice and visualized 
directly by confocal microscopy. Since all cells in Dct-Grm1/ K5-Edn3/ TYR-
CreERT2/ mT/mG mouse express tdTomato red fluorescence protein except 
GFP+ Tyr expressing cells or their progeny, whole mount visualization of the 
vessels allowed us to detect the presence of GFP+ cells directly. As shown in 
Figure 3.2, primary tumor derived GFP+ cells were found in all three vessels. Of 
note, GFP+ cells were always located in association with or within the vascular 
endothelial layer, not the outer smooth muscle layer. The GFP+ cells embedded 
into the endothelium resembled the vascular endothelial cells morphologically. It 
is noteworthy that GFP+ cells changed their morphology according to the 
vascular endothelium where they were found (Figure 3.2, i.e., vein associated 
GFP+ cells showed a different shape compared with the artery associated ones), 
further indicating the plasticity of tumor cells. Whole mount staining of CD31 and 
VE-cadherin was carried out on the vessels and 3D reconstruction showed 
results consistent with the ones obtained from the lung cryosections. The GFP+ 
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cells associated with the vasculature were clearly positive for CD31 and VE-
cadherin (Figure 3.3). 
3.2.2 Expression Pattern of Endothelial Cell Markers by GFP+ Cells is 
Dynamic  
The phenotypic plasticity of GFP+ cells was demonstrated by 
characterizing the expression of endothelial cell markers during tumor 
progression. In the primary tumors, GFP+ cells did not present detectable CD31 
expression (Figure 3.4A). In contrast, the majority of primary tumor resident 
GFP+ cells were VE-cadherin positive (Figure 3.4D), a feature of VM. In the lung 
vasculature, GFP+ cells associated with the vascular endothelium expressed 
both CD31 (Figure 3.4B) and VE-cadherin (Figure 3.4E). GFP+ cells populating 
the lung metastases lost the expression of both endothelial cell markers (Figure 
3.4C, F). The fact that GFP+ cells lost CD31 expression when they seeded the 
metastases was expected given that they originally did not express it in the 
primary tumor. It was surprising that they lost VE-cadherin expression as well, in 
that they were VE-cadherin positive at the beginning of the metastatic journey. 
As for what occurred in blood vessels, GFP+ cells also showed endothelial 
cell mimicry in lymphatic vessels. In the lymph nodes of Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mice, GFP+ cells were found associated with the 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) positive lymphatic 
vessel cells. LYVE-1 is strongly expressed by endothelial cells of normal 
lymphatic vessels but not blood vessels [27]. 90% of the intravascular (LYVE-1+ 
cell-lined vessels) GFP+ cells were also LYVE-1 positive (Figure 3.5A). GFP+ 
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cells that were associated to the lymph node blood vessels (LYVE1-/CD31+) 
expressed CD31 (Figure 3.5B) consistent with the results obtained from lung 
blood vessels. Although LYVE-1 can be used as a lymphatic vessel marker to 
discriminate lymphatic vessels from blood vessels in most tissues, it has been 
demonstrated to label various blood vessels in the mouse lung [28-30]. Indeed, 
we performed double immunostaining of CD31 and LYVE-1 on lung cryosections 
and found them to overlap considerably. In contrast, LYVE-1 only labeled the 
lymphatic vessels in lymph nodes though weak CD31 staining on some lymphatic 
vessels was also observed (data not shown). We found LYVE-1+/CD31+ 
intravascular GFP+ cells in the lung, but we cannot confirm the type of vessels 
they were associated with. However, GFP+ cells within the metastatic foci in the 
lung did not express LYVE-1 (Figure 3.5C).  
3.2.3 EndMT as a Potential Mechanism Underlying Dormant Tumor Cell 
Awakening 
Since the intravascular GFP+ cells in the metastatic sites acquired an 
endothelial cell phenotype, we wanted to find out if they could undergo EndMT as 
a way to regain the capacity to establish successful metastases. Endothelial-
mesenchymal transition has been proposed as an important mechanism that 
underpins the role played by tumor-derived endothelial cells in tumor progression 
[31]. The hallmarks of EndMT are the acquisition of the mesenchymal markers 
VIMENTIN and -smooth muscle actin (-SMA). We performed VIMENTIN and 
-SMA immunostaining on lung cryosections where GFP+ cells were found. 
VIMENTIN positive intravascular GFP+ cells were found in various areas of the 
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lung (Figure 3.6, arrowhead), but heterogeneity existed even between cells in 
close proximity (Figure 3.6, arrow). -SMA+ GFP+ cells were also identified in 
the lung. Interestingly, some CD31+/-SMA+ GFP+ cells were found inside 
alveolar capillaries (Figure 3.7, arrowhead), indicating an intermediate state of 
EndMT. Figure 3.8 shows the heterogeneity and plasticity of a small cluster of 
GFP+ cells located in an alveolar capillary with both CD31-/-SMA+ (Figure 3.8, 
arrow) and CD31+/-SMA+ (Figure 3.8, arrowhead) GFP+ cells. It is noteworthy 
that -SMA+ GFP+ cells were only found in smaller vessels (arterioles, 
capillaries). In contrast, GFP+ cells associated with larger vessels (pulmonary 
arteries) were always -SMA negative, and found wrapped around the -SMA+ 
smooth muscle cells and vascular endothelial cells (Figure 3.9) 
3.2.4 Plasticity and Heterogeneity of Metastatic GFP+ Cells 
The phenotypic change of GFP+ cells as they progressed from the 
primary tumor to the site of metastasis may require an initial process of de-
differentiation so they can acquire a novel fate. To evaluate if the intravascular 
GFP+ cells may also have gone through a stem-cell phenotype, immunostaining 
with the stem cell markers SOX2 and OCT4 was performed on lung cryosections 
of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. SOX2 and OCT4 positive 
metastatic melanoma cells were identified, but as for all the other markers tested, 
the staining pattern was quite heterogeneous (Figure 3.10).  
Connexin43 (Cx43) was shown to be involved in tumor/vascular 
endothelial cell communication in highly metastatic melanoma cells [32] and 
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breast cancer cells [33]. Stoletov et al. showed that metastatic melanoma and 
breast cancer cells used Cx43 to initiate brain metastatic lesion formation in 
association with the vasculature [34]. Similarly to what they found, we detected a 
small population of GFP+ metastatic melanoma cells associated with the 
vascular endothelium that were Cx43 positive (Figure 3.10). 
The heterogeneity and plasticity of primary tumor derived GFP+ cells were 
also observed in other metastatic organs. Immunostaining of VE-cadherin was 
performed on spleen and kidney cryosections from the Dct-Grm1/ K5-Edn3/ 
TYR-CreERT2/ mT/mG mouse where visible metastases were found. It is 
intriguing that no detectable or weak signal of VE-cadherin immunoreactivity was 
found on GFP+ cells scattered in the spleen and kidney, whereas GFP+ cells 
within the metastatic foci in the spleen were positive for VE-cadherin (Figure 
3.11A). S100 is used clinically for melanoma diagnosis, and we performed S100 
immunostaining on the lymph node cryosections where GFP+ cells were found. 
S100 was highly expressed in the metastatic lymph node but intravascular and 
circulating GFP+ cells did not show S100 expression (Figure 3.11B). 
3.3 Discussion 
In our study, we found that primary tumor derived Tyr expressing cells or 
their progeny mimicked endothelial cells when in contact with blood or lymphatic 
vascular endothelium during metastasis but lost the endothelial phenotype in the 
lung metastatic foci. The strong association between vascular endothelial cells 
and GFP+ tumor cells observed in the spontaneous mouse melanoma model 
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG is reminiscent of VM and mosaic 
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vessels. However, it is obviously distinct from these two mechanisms in that 1) 
the association was observed in metastatic sites not primary tumors, 2) GFP+ 
cell associated with original vasculature of the circulatory system, not newly 
formed vessels, 3) the metastatic GFP+ melanoma cells associated with the 
vascular endothelium were CD31 positive. Despite of these distinctions, similarity 
is evident because all these previously described mechanisms underlie the 
phenotypic plasticity of cancer cells by mimicking vascular endothelial cell 
properties. The possibility that metastatic GFP+ cells associated with the 
vasculature may achieve long-term survival because of the easy access to 
oxygen and nutrients also mirrors another tumor-vasculature pattern, vessel co-
option. But then again, the intravascular location of the GFP+ cells is different 
from that where tumor derived cells are found in vessel co-option. 
A recent review by Sun et al. suggested that a connection exists between 
VM and epithelial-to-endothelial transition (EET). They identified hypoxia, high 
interstitial fluid pressure and ECM remodeling as the likely factors that promote 
EET [35]. On the basis of the data provided in this study, we propose a 
melanoma (which is better characterized as a mesenchymal cell)-to-endothelial 
transition or transdifferentiation. This is not the first time that such a transition is 
suggested in the context of cancer.  Tumor-derived endothelial cells were 
recognized decades ago in human B-cell lymphoma and human neuroblastoma 
when tumor specific chromosomal alterations were identified in tumor endothelial 
cells through fluorescence in situ hybridization [36, 37]. Notwithstanding, the 
transdifferentiation of tumorigenic cells into endothelial cells was only recently 
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characterized in glioblastoma (GBM) using in vitro and in vivo evidence. In vitro, 
human glioma stem progenitor cells transdifferentiated into endothelial cells and 
formed tubular-like structures when cultured in endothelial differentiation medium. 
The expression of the endothelial markers CD31, CD34 and Von Willebrand 
factor (vWF) in glioma cells was induced by hypoxia or oxygen–glucose 
deprivation [38]. The in vivo evidence showing that GBM tumor cells 
transdifferentiated into CD31+ endothelial cells was first demonstrated through 
xenotransplantation. The authors found a GBM stem cell CD133+ subpopulation 
that had the capacity to differentiate along both tumor and endothelial cell 
lineages, and implicated VEGF and Notch pathways as important in this process 
[39]. These observations were corroborated by another group, who detected that 
a variable number (range 20–90%) of endothelial cells in human glioblastoma 
carried the same genomic alteration as tumor cells [40]. Glioblastoma cell to 
endothelial transdifferentiation was also reported in a syngeneic C6 glioma rat 
model [41] and xenotransplantation assay by Shaifer’s group [42]. Stronger 
evidence emerged from a study on a novel GBM mouse model using Cre/loxp-
controlled lentiviral vectors for tumor formation [43]. Tumor cells were labeled 
with GFP when lentiviral induced tumor formation happened and, notably, GFP+ 
tumor cells that associated with the vasculature expressed vWF, CD31, CD34 
and CD144. Further in vitro differentiation experiments revealed that hypoxia and 
independence of VEGF underlie the mechanism responsible for the cancer cell 
into endothelial cell transdifferentiation [44]. The latter was also shown by Seno’s 
group using miPS-LLCcm cells (a representative mouse induced pluripotent stem 
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cells, miPS, converted with culture medium from Lewis lung carcinoma cells) 
both in vitro [45-47] and in vivo [18].  
But why do tumor cells masquerade as endothelial cells? We showed in 
Chapter 2 that intravascular GFP+ cells in the lung of Dct-Grm1/ K5-Edn3/ TYR-
CreERT2/ mT/mG mice lost melanocytic lineage markers and recapitulated the 
state of dormancy. If the transdifferentiation of melanoma cells into endothelial 
cells is the next step in the process, then endothelial cell mimicry may serve as a 
mechanism underlying metastatic dormancy to help tumor cell survival or escape 
immune surveillance.  
Although endothelial cell markers CD31 and CD34 were detected in 
histological sections of uveal melanoma [48] and cutaneous melanoma [49], their 
presence was not connected to tube-like structures and the origin of the 
endothelial marker positive cells was not defined. Dudley’s group described a 
CD31 positive cutaneous melanoma cell population that was also positive for the 
melanocytic marker Tyr. These CD31+/Tyr+ VM-competent tumor cells existed 
as stable, yet hidden subpopulations in heterogeneous melanomas [50]. The 
population of CD31+ cells described in this study is different in that they 
transitioned from expressing Tyr to expressing CD31 during the dissemination 
process and reverted back to expressing Tyr upon successful metastasis 
formation. VE-cadherin is a well-recognized marker for VM, GFP+ cells within the 
primary tumors of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were positive 
for VE-cadherin and maintained VE-cadherin expression during the metastatic 
process. However, GFP+ cells lost VE-cadherin expression in the metastatic foci 
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in the lung. Given the rich vasculature and gas exchange function of the lung 
tissue, this result could be interpreted with the assumption that VM is not 
necessary for the growth of metastases. Nonetheless, the internal or external 
factors required for triggering the dynamic gene expression changes of 
metastatic melanoma cells in Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice 
are not clear. The study led by Kaessmeyer et al. demonstrated that the co-
culture of lung endothelial cells and squamous or adenocarcinoma lung cancer 
cells resulted in a contact dependent “CD31 staining switch”, shown by the 
acquisition of CD31 expression of the tumor cells in direct contact with 
endothelial cells. This study suggested that tumor plasticity might be influenced 
by the endothelial microenvironment and by direct interactions with endothelial 
cells [51].   
Endothelial-mesenchymal transition featured by the loss of endothelial 
marker expression, such as CD31, with the concomitant increase in 
mesenchymal marker expression, such as -SMA / VIMENTIN / FSP1, was 
originally observed during heart development where a population of endocardial 
cells differentiated into mesenchymal heart cushion cells forming cardiac septa 
and valves [52]. Later on, this phenotypic transition was shown to contribute to 
cardiac fibrosis [53] and carcinoma associated fibroblasts [54] in mouse models 
[55]. Transforming growth factor-beta (TGF-) and bone morphogenetic protein 
(BMP) family of growth factors are key players in EndMT [56, 57]. Generation of 
mesenchymal cells from endothelium is a crucial step in the multipotent 
differentiation of endothelial cells and acquisition of a stem-like phenotype was 
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observed in endothelium during EndMT [57, 58]. The role of EndMT in cancer, 
especially during metastasis, has only recently been recognized. Endothelial-
mesenchymal transition was observed in endoglin-deficient vasculature and this 
process facilitated tumor cell intravasation in multiple mouse models [59]. The 
observation that cancer cells can acquire an endothelial-like phenotype and be 
incorporated into vessels suggested an extra role for EndMT in tumor 
progression. Selek et al. proposed that through EndMT, endothelial-like cancer 
cells can transdifferentiate into cancer associated fibroblasts or mesenchymal 
cancer stem cells (MCCs), and that either one can contribute to tumor 
progression. Additionally, disruption of tumor vasculature by antiangiogenic 
therapies may result in the dissemination of MCCs responsible for latent 
metastasis[31]. 
Despite of substantial evidence supporting the existence of tumor derived 
endothelial cells and the role played by EndMT in tumor progression, a robust 
connection between them and tumorigenesis is still missing, particularly in 
melanoma. The results presented here showed that in vivo metastatic melanoma 
cells can transdifferentiate into endothelial cells during metastasis and the 
subsequent transition into a mesenchymal phenotype may contribute to latent 
metastasis in the lung. We hope these findings will fill in the gaps in melanoma to 
endothelial transition, and offer a possible new mechanism underlying melanoma 
latent metastasis. 
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Figure 3.1 GFP+ cells inside the pulmonary vasculature expressed endothelial cell markers. 
Immunostaining on lung cryosections indicated the primary tumor derived GFP+ cells were positive for endothelial 
cell specific markers CD31 (A-D) and VE-cadherin (E-H). 
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Figure 3.2 Confocal and 3D reconstruction of blood vessels. 
2-3mm segments of pulmonary artery, pulmonary vein and aorta were dissected and directly visualized under the 
confocal microscope. GFP+ tumor cells were found within the endothelial layer of all three types of vessels. GFP+ 
cells exhibited different morphologies that corresponded to the type of blood vessel they were located. 
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Figure 3.3 Whole mount staining and 3D confocal reconstruction of arteries 
where GFP+ cells were found. 
Top panel 3D reconstruction of the whole mount staining showed that GFP+ cells 
integrated into the vascular endothelium and expressed CD31 and VE-cadherin 
(top surface is the endothelium of the vasculature, bottom is the smooth muscle 
cell layer negative for endothelial cell markers). Lower panel is one section from 
the 3D reconstruction confirming GFP+ cells are positive for endothelial markers 
CD31 and VE-cadherin. 
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Figure 3.4 Plasticity of GFP+ cells from primary tumor sites to lung metastases. 
GFP+ cells did not express endothelial cell marker CD31 in the primary tumors 
(A, only endothelial cells in the blood vessels were CD31+) but were VE-cadherin 
positive (D). GFP+ cells were positive for both CD31 and VE-cadherin in the lung 
vasculature (B, E), but lost the endothelial cell markers in lung metastases (C, F). 
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Figure 3.5 Endothelial cell mimicry in lymph nodes. 
Primary tumor derived GPF+ cells in the lymph nodes expressed LYVE-1 inside lymphatic vessels (A) and CD31 
inside the blood vessels (B) and were strongly associated with the vascular endothelium no matter which type of 
vessels they were in.  GFP+ cells lost the lymphatic endothelial marker LYVE-1 inside the lung metastatic foci (C). 
Note, one GFP+ cell outside the metastatic foci in the lung was LYVE-1 positive (C, star), although we cannot 
identify whether this is a lymphatic vessel or blood vessel. 
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Figure 3.6 Immunostaining of VIMENTIN on lung cryosections. 
VIMENTIN positive (arrowhead) and negative (arrow) GFP+ cells were identified 
at various locations in the lung (A), 3D projection from confocal z-stack images 
(B) confirmed that primary tumor derived GFP+ metastatic melanoma cells 
expressed mesenchymal cell marker VIMENTIN.  Green, GFP; red, VIMENTIN; 
blue, DAPI.
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Figure 3.7 GFP+ metastatic tumor cell acquired mesenchymal marker -SMA 
expression in the lung. 
GFP+ cell (arrowhead) maintained endothelial cell marker CD31 and acquired 
the expression of mesenchymal cell marker -SMA, indicating an intermediate 
state of EndMT. A CD31+/-SMA+/ GFP- cell (arrow) in close proximity to the 
GFP+ cell shows the same phenotype. It is possible that this is an authentic 
vascular endothelial cell undergoing EndMT, or a metastatic cell that was not 
labeled with GFP. Lower right picture shows a higher magnification of the boxed 
area. Green, GFP; red, -SMA; blue, DAPI; magenta, CD31. 
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Figure 3.8 -SMA and CD31 immunostaining on lung sections. 
A cluster of GFP+ cells located at the alveolar capillary. Both CD31-/-SMA+ 
(arrow) and CD31+/-SMA+ (arrowhead) GFP+ cells were found. No cell with 
strong CD31+/-SMA- immunoreactivity was found in this view. Green, GFP; red, 
-SMA; blue, DAPI; gray, CD31. 
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Figure 3.9 3D reconstruction of GFP+ cells located in the pulmonary artery. 
3D reconstruction of GFP+ cells in lung cryosection showed three -SMA 
negative GFP+ cells (arrowhead) wrapped around one -SMA positive smooth 
muscle cell (arrow). GFP, green; red, -SMA; blue, DAPI.
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Figure 3.10 Plasticity of GFP+ cells associated with the lung vasculature. 
Immunostaining on lung cryosections was performed. Intravascular GFP+ cells showed stem cell marker SOX2 
and OCT4 immunoreactivity. A subpopulation of GFP+ cells expressed gap junction protein connexin43. Arrows 
indicate the immunoreactive GFP+ cells.
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Figure 3.11 Plasticity and heterogeneity of melanoma metastatic cells in other 
organs. 
Immunostaining of various markers in spleen, kidney and lymph nodes from Dct-
Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. Primary tumor derived GFP+ cells 
scattered in the spleen had undetectable VE-cadherin expression while GFP+ 
cells inside the metastatic foci in the spleen showed strong VE-cadherin 
expression (A, top panel). In the kidneys, no detectable or weak signal was 
detected on GFP+ cell (A, lower panel). S100 staining was performed on lymph 
node cryosections where GFP+ cells were found. GFP+ cells associated with the 
vascular endothelium or within the lumen were negative for S100 (B).
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4. CONCLUSIONS AND FUTURE DIRECTIONS 
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4.1 Conclusions 
Melanoma is not the most common type of skin cancer, but it causes the 
most deaths. It is notorious for the high propensity to metastasize and poor 
response to therapies. Numerous questions remain unanswered regarding the 
process of melanoma metastasis, which is partially due to the lack of proper 
melanoma metastasis mouse models. The Dct-Grm1/ K5-Edn3 mice not only 
spontaneously develop melanoma tumors on the ear, tail and dorsal skin, but 
also show metastases in the lung, providing an ideal system to identify the 
intrinsic tumor initiating capacity of specific cell subpopulations within an 
unperturbed tumor environment. 
Using Cre/loxp system, I was able to label the primary tumor resident Tyr 
expressing cells with GFP and perform lineage tracing of the GFP+ cells during 
metastasis in the Dct-Grm1/ K5-Edn3 mice. I showed that the primary tumor-
derived differentiated Tyr expressing cell subpopulation or their progeny 
possessed metastasis-initiating capacity and exhibited phenotypic plasticity 
during the metastatic process. The GFP+ metastatic melanoma cells could reach 
the distant organs and seed metastases successfully. Numerous GFP+ cells 
were detected inside the vasculature and established strong association with the 
vascular endothelium in the organs where metastases were identified. 
Interestingly, GFP+ cells lost the pigmentation as well as melanocytic lineage 
markers upon contact with the vascular endothelium was established. 
Vasculature-associated GFP+ cells did not express melanoma stem cell markers, 
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however, they mimicked vascular endothelial cells by expressing CD31 and VE-
cadherin. Three-dimensional reconstruction by confocal microscopy further 
identified the endothelial cell mimicry of GFP+ cells. The phenomenon was also 
observed in the lymphatic vessels of lymph nodes. The phenotypic plasticity of 
metastatic GFP+ cells was also corroborated by the fact that GFP+ cells lost the 
endothelial cell marker expression and resumed pigment production when 
populating the metastatic foci. Furthermore, the morphology and distinct 
phenotypic entities of GFP+ cells in different metastatic organs substantiated the 
plasticity of metastatic melanoma cells. 
GFP+ cells in the lung vasculature were found positive for mesenchymal 
markers -SMA or VIMENTIN. Assuming that the intravascular GFP+ cells were 
the potential metastasis-initiating cells in the lung of Dct-Grm1/ K5-Edn3/ TYR-
CreERT2/ mT/mG mice, I propose a two-step mechanism underlying melanoma 
metastasis that involves melanoma-endothelial cell transition at the primary 
tumor site and EndMT at the metastatic site. The proposed model based on the 
experimental observations and implied suggestions for the process of melanoma 
metastasis in the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mouse is 
summarized in Figure 4.1. 
In conclusion, I have provided direct evidence that a specific cell 
subpopulation within the primary tumor possesses tumor initiating capacity in the 
context of metastasis. Lineage tracing of the metastatic melanoma cells in vivo 
indicated the phenotypic plasticity of cancer cells. My results will not only 
enhance our understanding of melanoma metastasis, but also provide insights 
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for the diagnostics and re-examination of melanoma patients aiming at the 
detection of “vascular hidden” metastatic melanoma cells. 
4.2 Future Directions 
The heterogeneity of tumors including melanoma has been recognized for 
decades addressing the varied tumor initiating capacities of cell subpopulations 
within the same solid tumors [1]. Although the cancer stem cell model has been 
proposed for  melanoma [2], it remains controversial and several questions are 
still unanswered. In this study, I have shown that the more differentiated Tyr 
expressing cells or their progeny (GFP+) possessed metastasis-initiating 
capacities and seeded successful metastases in various distant organs of the 
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. However, the exact 
subpopulation of the primary tumor derived GFP+ cells that initiated the distant 
metastasis is not clear. Considering this, it would be of great interest to isolate 
the circulating GFP+ cells and the lung vasculature-associated GFP+ cells in the 
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice and characterize the 
tumorigenic capacities of these two populations. High deformability of Sox2-
expressing melanoma cells grown in 3D soft fibrin gels has recently been shown 
to facilitate the extravasation of metastatic cells [3]. Given the morphological 
plasticity of metastatic GFP+ cells I observed in the established lineage tracing 
system, it is worthwhile to test the mechanical stiffness of the two GFP+ cell 
subpopulations. RNA-sequencing would be another approach to further identify 
the mechanism underlying the distinct tumorigenic capacities, if any, between the 
circulating GFP+ cells and the lung vasculature-associated GFP+ cells. 
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I proposed the melanoma-endothelial cell transition as the first step for Tyr 
expressing cells to successfully metastasize based on the finding that CD31+ 
GFP+ cells were identified inside the vasculature at the primary tumor site. Most 
of the studies focusing on characterizing tumor derived endothelial cells have 
been carried out in the context of glioma. Hypoxia has been suggested as a 
promoter of glioma cell transdifferentiation [4, 5]. Although melanoma tumors 
from the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were suggested to 
display hypoxic areas [6], I did not observe sufficient CD31+ GFP+ cells within 
the primary tumor mass. One possibility to explain this finding is that it was very 
difficult to detect single cells due to the extensive amount of pigmentation in the 
tumor sections. However, alternative factors other than hypoxia may be the 
trigger of melanoma to endothelial cell transdifferentiation. For example, lung 
carcinoma cells co-cultured with human microvascular lung endothelial cells 
became strongly positive for CD31 as a non-angiogenic process for blood supply 
[7].  To characterize the potential effects of tumor-endothelial cell contact in 
melanoma, it would be interesting to perform similar co-culture of human 
microvascular lung endothelial cells with human melanoma cells. To better 
replicate the context of my in vivo experiments, human melanoma cells 
overexpressing Grm1 would be the ideal cells to employ. 
Furthermore, in the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice, 
primary tumor derived GFP+ cells associated with lung vasculature were not 
proliferating or dying and the number of those intravascular cells far exceeded 
the number of metastatic foci in the lung. The above observations imply the 
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features of metastatic dormancy. The presence of lung infiltrates surrounding the 
GFP+ cell-containing vessels raises the question of why GFP+ cells were found 
embedded in the vascular endothelium. Suppression of the immune system in 
Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice will allow us to identify whether 
lymphocyte infiltrates are the main suppressor of extravasation or EndMT of 
GFP+ cells. Alternatively, the immune response observed is possibly a general 
phenomenon of metastasis, and the intravascular GFP+ cells are intrinsically 
programmed for remaining in a dormant state and can only be re-awaken upon 
exposure to as yet unidentified environmental factors. Further studies to 
determine both the intrinsic and extrinsic cues underlying entry into and exit from 
dormancy state would be very valuable. 
Late recurrence has been observed in human melanoma patients [8], 
indicating the presence of residual cancer cells that escape the detection of 
available techniques. Based on my observations in the mouse model, it is highly 
possible that metastatic melanoma cells cease to express most, if not all, 
melanocytic features and masquerade themselves as other cell types and 
become clinically invisible. Labeling of primary tumor cells is impossible in human 
patients and the loss of pigmentation of the intravascular metastatic melanoma 
cells challenges their detection in metastatic organs. Other than the genetic 
tracing of tumor cells in mouse models, analysis of tumor specific chromosomal 
alterations[9-11] was used to identify the tumor derived endothelial cells in 
human samples. BRAF mutations are found in approximately 60% of somatic 
melanoma cases [12]. An antibody against BRAF V600E, the mutated form of 
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BRAF, is commercially available. One possible alternative for detecting these 
“invisible” metastatic cells in human melanoma samples is to use immunostaining 
or flow cytometry with Anti-BRAF V600E and endothelial cell specific markers. If 
a population of double positive cells in the primary or metastasis melanoma 
samples can in fact be revealed, current strategies for melanoma metastasis 
diagnostics and metastasis-targeted therapies need to be enhanced taking the 
existence of these cells into consideration. 
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Figure 4.1 Diagram of melanoma metastasis in the Dct-Grm1/ K5-Edn3/ TYR-
CreERT2/ mT/mG mice. 
Primary tumor resident Tyr expressing cells express VE-cadherin, indicating VM. 
Metastatic Tyr expressing cells or their progeny (GFP+, green color cells in 
diagram) enter the vasculature through extravasation or transdifferentiate into 
CD31+ endothelial cells establishing associations with the vascular endothelium. 
Intravascular GFP+ cells move towards the metastatic site as circulating tumor 
cells (CTCs) or may roll over the vascular endothelium during endothelial mimicry. 
EVMM was only observed in metastatic tumor at the primary tumor site, not 
distant organs in the Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice. In the 
lung, intravascular GFP+ cells form metastases through extravasation and grow 
using angiogenesis or vessel co-option. A subset of CD31+ GFP+ cells in smaller 
pulmonary vessels went through EndMT, suggesting a potential mechanism for 
the metastasis-initiating capability of vasculature-associated metastatic cells. 
Intravascular growth of GFP+ cells in the pulmonary capillaries with subsequent 
extravasation when intravascular micro-metastatic foci outgrow the vessels they 
are in can be another source for metastases formation. 
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MATERIALS AND METHODS 
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Mice and Genotyping 
The K5-tTA;TRE-Edn3-lacZ (K5-Edn3, for simplicity) mice, which 
overexpress Edn3 under the keratinocyte promoter Keratin 5 resulting in a 
hyperpigmentation phenotype due to the accumulation of melanocytes at the 
dermal-epidermal junction, were generated in our laboratory[1]. The Tg(Grm1) 
Epv (E) mice (Dct-Grm1, for simplicity, a gift from Dr. William Pavan, NIH) 
[2]express the metabotropic glutamate receptor 1 under the regulation of the 
melanocyte specific Dopachrome tautomerase promoter and develop 
spontaneous melanocytic tumors on the ear and tail, but rarely metastasize. The 
progeny from the K5-Edn3 mice and Dct-Grm1 mice mating carrying all 
transgenes, Dct-Grm1/ K5-Edn3, were used in this study as a melanoma mouse 
model. The Dct-Grm1/ K5-Edn3 mice not only spontaneously develop melanoma 
on the ear, tail and dorsal skin, but also metastasize to the lung with 80% 
penetrance. 
To genetically label Tyrosinase expressing cells in the Dct-Grm1/ K5-Edn3 
mice and establish an in vivo lineage tracing system, Cre/loxp system was used 
in this study. TYR-CreERT2 mice are widely used for melanoma or melanocyte 
related studies. These mice have expression of CreERT2 fusion protein directed 
by mouse Tyr promoter/enhancer regions. When bred with mice containing loxp-
flanked sequences, tamoxifen/4HT-inducible Cre-mediated recombination results 
in the deletion of the floxed sequences in the Tyr-expressing cells of the offspring. 
For the Cre-reporter mice, the bifluorescent mice mT/mG [3] was selected due to 
the following reasons. First, it not only labels cells after Cre-mediated 
 121 
recombination, but also labels non-recombined cells. Second, the double 
fluorescent reporter genes in these mice simplify the visualization of recombined 
and non-recombined cells without the addition of an exogenous enzymatic 
substrate like β-Galactosidase used in LacZ reporter mice. Third, the membrane 
targeted tdTomato and GFP fluorescent proteins in mT/mG mice allows the 
labeling to be visualized at single cell resolution which is important for lineage 
tracing. The Cre/loxp system in this study using TYR-CreERT2 and mT/mG mice 
will be established through the mating of those two mouse strains resulting in the 
offspring TYR-CreERT2/mT/mG mice. 
The genotyping of the Dct-Grm1/K5-Edn3/TYR-CreERT2/mT/mG mice was 
carried out by DNA extraction from a small piece of the tail using standard 
procedures and followed by PCR using the appropriate primers (Table S2) for 
each transgene ([1, 2], The Jackson Laboratory). Mice were housed in the 
University Animal Care Facility at Florida International University. The animal 
protocol was approved by the Committee on Animal Care and Use and Office of 
Sponsored Research at Florida International University and all Institutional 
Animal Care and Use Committee regulations were followed. 
4HT Topical Painting on Tumors 
Topical administration of 4HT was performed by preparing a 50mg/ml 
solution of 4HT (Sigma, H6278) in DMSO and applying enough solution to wet 
the tumors with a small paint brush. Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG 
mice were monitored for tumor appearance on the tail and dorsum. As soon as 
the first tumor appeared, we topically painted 4HT on the primary tumors twice a 
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day for three consecutive days during 3~4 weeks to ensure the labeling of most 
Tyr expressing cells within the primary tumors. Mice were monitored for primary 
tumor growth until 30 weeks, unless euthanasia was necessary due to poor 
health. As such, mice were euthanized at different times after the first painting 
that varied from 2 weeks to 30 weeks. After euthanasia, tumor burdened mice 
were examined for the presence of metastases in the lungs as well as other 
organs under the dissecting microscope. Pigmented lesions in the lung ranged 
from large macro-metastatic tumors (>1mm in diameter) to smaller pigmented 
lesions that were clearly visible with the naked eye (pepper-like micro-
metastases) or much smaller micro-metastases that were only visible under a 
dissecting microscope. 
Immunofluorescence Staining 
Harvested organs were fixed in 4% paraformaldehyde (PFA) overnight at 
4° C and washed in 1X PBS. Organs were cryo-protected by sequential 
immersion in 15% and 30% sucrose and then embedded with OCT. 10m 
sections were obtained for immunofluorescence staining. Sections were 
incubated in blocking buffer (10% normal serum, 0.3% Triton X-100, 1%BSA 
power) at room temperature for 1 hour and followed by primary antibody 
incubation at room temperature for 1 hour or at 4° C overnight. Primary 
antibodies were diluted in dilution buffer (1% BSA, 1% normal serum, 0.3% Triton 
X-100). Sections were thoroughly washed before incubation in secondary 
antibodies for 1 hour at room temperature. Sections were mounted with 
fluoroshield mounting medium with DAPI (Abcam, ab104139) and visualized on a 
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Leica Leitz DMRB fluorescent microscope or Olympus Confocal BX61 
microscope. For pigment bleaching on primary tumor sections, slides were 
incubated in 10% H2O2 in PBS at room temperature for about 16 hours followed 
by regular immunostaining. Where necessary, tissue GFP and tdTomato 
fluorescence from the mT/mG allele were photobleached by treatment with 3% 
H2O2 in methanol and illumination on a fluorescent light box for 4 hours to 
overnight at 4°C. GFP signal was amplified by anti-GFP antibody if necessary. 
Primary antibodies used: GFP (1:500, Aves Labs, GFP-1020), Ki67 (1:200, 
Abcam, ab15580), Cleaved Caspase 3 (1:200, CST, 9664s), Rat CD31 (1:200, 
eBioscience, 14-0311-82), Rabbit CD31 (1:200, Abcam, ab28364), CD45 (1:200, 
Biolegend, 103101), CD3 (1:200, Novusbio, NB600-1441), P75 (1:200, Millipore, 
ab1554), Nestin (1:50, Millipore, MAB353), SOX10 (1:50, Santa cruz, sc17342), 
TYR/TRP1 (1:200, gift from Dr. Vincent Hearing), LYVE-1 (1:200, eBioscience, 
14-0443-80), VE-cadherin (1:200, Abcam, ab33168), SOX2 (1:200, Abcam, 
ab97959), OCT4 (1:200, Abcam, ab18976), Connexin43 (1:200, CST, 3512), 
S100 (1:200, Sigma, S2644). Secondary antibodies used: anti-chicken 488 
(1:500, Abcam, ab150169), anti-rabbit 594 (1:400, Invitrogen, A11012), anti-
rabbit 647 (1:400, Abcam, ab150075), anti-rat 647 (1:400, Abcam, ab150159). 
H&E Staining of Lung Cryosections 
Cardiac perfusion with PBS was performed immediately after euthanasia. 
After the PBS perfusion, lungs were infiltrated with OCT through the trachea by a 
18G needle. Sections were subjected to H&E staining as follows: dH2O for 30 
secs; Gill’s Hematoxylin 3 (VWR, 87001-924) for 5 mins; running tap water for 1 
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min; Clarifier (VWR, 89237-218) for 15 secs; dH2O for 30 secs; Bluing Agent 
(VWR, 95057-852) for 45 secs; dH2O for 30 secs; 95% ethanol for 15 secs; 
Eosin (poly scientific R&D Crop, s2186) for 45 secs; 95% ethanol for 30 secs; 
100% ethanol for 10 secs; Xylene for 15 secs; Xylene for 1 min; dry slides and 
mount with cytoseal (xylene-based medium). 
Counting of Ki67+ or Caspase 3+ Intravascular GFP+ Cells in the Lung 
15 non-parallel lung cryosections per Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ 
mT/mG mouse (n=3) were immunostained for Ki67 or Caspase 3 together with 
GFP. Total intravascular GFP+ cells were counted for each mouse. Among the 
intravascular GFP+ cells counted, double positive (Ki67+GFP+ or Caspase 
3+GFP+) cells were counted. Total number of intravascular GFP+ cells varied 
from 29 to 243 per mouse. Percentage of Ki67+ or Caspase 3+ intravascular 
cells was obtained through double positive intravascular cells/total intravascular 
GFP+ cells. 
Timing of Metastatic Cell Dissemination 
Adult Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mice were separated 
into three groups based on the stage of tumor development on the tail: 1) before 
nevus stage, where no noticeable tumor or nevus was observed; 2) nevus stage, 
where the lesion was less than 1mm in height; 3) tumor stage, where a clearly 
detectable tumor had formed. 4-HT was topically applied to the nevus/tumor site 
by a small painting brush twice a day for three consecutive days. For the before 
nevus stage, 4-HT was applied to the tail of Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ 
mT/mG mice that were 8-month-old yet without detectable tumor or nevus. The 
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proximal 3-4 cm of the tail where lesions generally develop was 4HT painted 
twice a day for three consecutive days. 
Whole Mount Confocal Imagining and Immunofluorescence Staining of 
Blood Vessels 
A small segment (2-3mm length) of pulmonary artery, pulmonary vein, 
thoracic aorta or abdominal aorta was used for whole mount imaging or staining. 
The vessel segments were dissected and fixed in fresh 4% PFA in PBS at 4C 
overnight. For confocal imaging, the vessels were cut open and mounted flat on 
glass slides with fluoroshield mounting medium with DAPI (Abcam, ab104139). 
For immunofluorescence staining, vessels were cut open and washed in 1% 
Triton X-100 in PBS for 40 minutes and blocked in 1% Triton X-100, 10% FBS in 
PBS for 90 minutes at room temperature. Primary antibodies were diluted in 
blocking buffer as described previously; vessels were incubated with primary 
antibodies in 0.5mL PCR tube at 4C for 20 hours with shaking. After PBS 
washing for 30 minutes twice, secondary antibodies were applied in blocking 
buffer for 2 hours. Vessels were washed in PBS thoroughly and mounted with 
fluoroshield mounting medium with DAPI. Z-stack images were taken from the 
top layer (endothelial layer) to the bottom layer (smooth muscle layer) at a step 
size 0.5 to 1m, 30 to 60 z-slice images were taken with Olympus Confocal BX61 
microscope. 3D reconstruction or 3D projection of the z-stack images was 
performed with Fiji-ImageJ software. 
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Figure S 1. GFP+ cells in the tail tumors after 4HT induction. 
Primary tumor cryosections 7 months after the first 4HT painting. 4HT topical 
painting was performed once (twice a day for three consecutive days) when the 
tail tumor was at the nevus stage. Few GFP+ cells were identified in the tumor 
(A). 4HT topical painting was performed for 4 weeks since the nevus stage. 
Numerous GFP+ cells were found in the tumor (B). Sections were counterstained 
with DAPI (blue). 
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Ear Tag# 
&Genotype 
4HT Painting 
Site 
Painting 
Times 
Lung 
Metastasis 
GFP+ 
Cells 
in 
Lung 
GFP+ 
Cells in 
Lymph 
Nodes 
GFP+ 
cells in 
Other 
Organs 
#298* tail tumor 2 micro-
metastasis 
no no NA 
#875* tail tumor 5 micro-
metastasis 
no no NA 
#300* tail tumor 5 micro-
metastasis 
yes no NA 
#396* dorsal tumor 
with 2-3 mm 
in height 
3 micro-
metastasis 
yes no NA 
#471* tail tumor 4 no no NA NA 
#231* tail tumor 8 micro-
metastasis 
no yes NA 
#365* tail tumor 5 micro-
metastasis 
no no NA 
#946* tail & dorsal 
tumor with 2-
3 mm in 
height 
tail 4, 
dorsal 1 
micro-
metastasis 
yes yes NA 
#997* tail & dorsal 
tumor 
tail 1, 
dorsal 5 
micro-
metastasis 
yes yes NA 
#369* tail & dorsal 
tumor 
tail 4, 
dorsal 7 
pepper like 
micro-
metastasis 
yes yes NA 
#443* dorsal tumor 4 no yes yes NA 
#476* dorsal tumor 1 micro-
metastasis 
no yes NA 
#451* tail & dorsal 
tumor 
tail 3, 
dorsal 5 
micro-
metastasis 
yes NA NA 
#479* dorsal tumor 10 macro-
metastasis 
yes yes spleen, 
kidney 
#425* tail tumor 8 micro-
metastasis 
no NA  
Control (n=10) 
Dct-Grm1/K5-
Edn3/mT/mG 
 1~8 yes no NA NA 
Control (n=3) 
Dct-Grm1/ K5-
Edn3/ TYR-
CreERT2/ 
mT/mG 
dorsum 
(before 
nevus) 
1 no no NA NA 
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Table S 1. 4HT induction of GFP expression and lung metastasis. 
Macroscopic metastases in other organs were only observed in mouse#479, and 
GFP+ cells were found in those organs. When macroscopic metastases were not 
found, organs were not checked for GFP+ cells (NA), except brains (no GFP+ 
cells in any of the mice). Painting time “1” means 4HT topical application twice a 
day for three consecutive days. Every painting was performed for a duration of 
three or four weeks. All paintings started from nevus stage, unless specified, and 
lasted until the mouse was euthanized. Painting of dorsal tumors may have 
started post nevus stage because of the difficulty in detecting the nevi under the 
coat. For genotype, “*” indicates Dct-Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG 
experimental mice, genotypes of control mice were specified in table.
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Figure S 2.Primary tumor derived GFP+ green cells were found in different 
organs. 
 A-E, lung; F-G, spleen; H-I, kidney. Note, most of the green cells were single 
cells with an elongated shape; clusters of cells were mostly confined to micro-
metastasis (D) or macro-metastasis (F, pigmented lesion in the spleen). Most 
GFP+ cells found in the lung vasculature were in close association with the 
vascular endothelium (A-C) with rare cases in the lumen of the vasculature 
corresponding to the circulating cells (E). Scattered single GFP+ cells were 
detected in the spleen (G), between the renal tubules (H) and adjacent to 
glomeruli (I).
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Figure S 3. Cleaved Caspase 3 staining on the lung. 
One GFP+ cell in contact with the pulmonary vascular endothelium was positive for Caspase 3, indicating this cell 
underwent apoptosis. 
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Figure S 4. Ki67 staining on lung perivascular infiltrates. 
Most lymphocytes inside the infiltrates were Ki67 positive indicating the activation of immune response towards the 
emergence of GFP+ cells inside the vessels. 
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Figure S 5. Metastatic tumors on the skin. 
4HT was applied to the dorsal tumor and distal tail tumor (arrowhead) of the Dct-
Grm1/ K5-Edn3/ TYR-CreERT2/ mT/mG mouse shown here. Proximal tail tumor 
(boxed area) was mostly constituted by GFP+ cells indicating it was a metastasis 
derived from the Tyr+ cells from the distal tail or dorsal tumor.  
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Figure S 6. GFP+ cells inside the alveolar capillaries were CD31 positive. 
Lung cryosections (A-H) depicting GFP +cells (A, E) inside alveolar capillaries, were labeled with CD31 antibody (B, 
F) and counterstained with DAPI (C, D). Some GFP+ cells were CD31 positive (D, H, arrowhead) and some were 
not (H, arrow) indicating the heterogeneity of metastatic tumor cells. 
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Gene Sequence 5' --> 3' 
TYR-
CreERT2 
CTC TGC TGC CTC CTG GCT TCT 
CGA GGC GGA TCA CAA GCA ATA 
TCA ATG GGC GGG GGT CGT T 
mT/mG GCG GTC TGG CAG TAA AAA CTA TC 
GTG AAA CAG CAT TGC TGT CAC TT 
CTA GGC CAC AGA ATT GAA AGA TCT 
GTA GGT GGA AAT TCT AGC ATC ATC C 
Dct-Grm1 CCGGGTCCGCATTAATCTTATCTA 
GGTAGCATACGGTTCCACGCA 
K5-Edn3 CCAGGTGGAGTCACAGGATT 
ACAGAGACTGTGGACCACCC 
GGCCTGTGCACACTTCTGT 
TCCTTGTGAAACTGGAGCCT 
Table S 2. Primers for mouse genotyping.
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